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lipids
Cardiovascular disease (CVD) is the single largest cause of
death in the developed countries and is among the leading
causes of death and disability in the developing nations as
well. There are an estimated 31.8 million people living with
coronary artery disease (CAD) in India alone.1 Furthermore, in
contrast to developed countries, CVD tends to occur at a
younger age in Indians with 52% of CVD deaths occurring
under 70 years and 10% of heart attacks occurring in subjects
<40 years. The age-standardized estimates for disability-
adjusted life-years (DALY's) lost due to CAD are three times
higher in India than in developed countries.
Of the defined traditional CV risk factors, dyslipidemia is
perhaps the most common and easily controllable risk factor.
Worldwide, high cholesterol levels are estimated to cause 56%
of ischemic heart disease and 18% of strokes, amounting to 4.4
million deaths annually. At the same time, the CV benefits of
lipid lowering have also been well researched. A review of ten
large cohort studies reported that a decrease of 10.8 mg/dlin
cholesterol concentration was associated with a decrease in
risk of ischemic heart disease by 54% at age 40, 39% at age 50,
27% at age 60, 20% at age 70 and 19% at age 80.2 Further, the
meta-analysis of trials to reduce serum cholesterol concen-
trations showed that for a similar reduction in serum
cholesterol, there was a 7% reduction in ischemic heart dis-
ease events for men enrolled in the trial for less than 2 years,
22% for those enrolled between 2 and 5 years and 25% for
those enrolled between 5 and 12 years.2 Thus, sustained
cholesterol lowering, using either drug therapy or dietary in-
terventions, reduces the occurrence of ischemic events across
all age groups. Although there are distinct epidemiological
difference between South-Asians and the western pop-
ulations, overall CV risk factors are same in both. In fact, as
shown in the INTERHEART study, dyslipidemia appears to be
the strongest contributor of acute myocardial infarction (MI)
in South-Asians.3
Numerous studies conducted in Indians have revealed that
various forms of dyslipidemia such as high total and low-
density lipoprotein cholesterol (TC and LDL-C), low high-
density lipoprotein cholesterol (HDL-C) and high tri-
glycerides (TG) are highly prevalent. At the same time, while
extensive guidelines are available for management of dysli-
pidemia in US and Europe, no specific guidelines exist for lipid
management among Indians. Consequently, Indian physi-
cians need to resort to the western guidelines only for man-
aging lipid abnormalities in Indian patients, which, for several
reasons, is not a very desirable practice. As outlines below,
Indians are known to have significant socioeconomic, cul-
tural, lifestyle and genetic differences that directly or indi-
rectly impact prevalence and management of dyslipidemia
and CVD-
 The pattern of dyslipidemia is different in Indians. The
LDL-C levels are not very high but there is greater pre-
ponderance ofmore atherogenic small, dense LDL particles
as compared to Caucasian subjects. In addition, the TG
levels are usually elevated and HDL-C levels are low. Thispattern of dyslipidemia, which is known as ‘atherogenic
dyslipidemia’, is a quite common in South Asian
populations.
 The prevalence and the pattern of concomitant CV risk
factors that modulate the impact of dyslipidemia on CV
risk (e.g. truncal obesity, metabolic syndrome and dia-
betes) are also different in Indians.
 Early age of onset of CVD in Indians renders the prediction
of CV risk a challenging task. Most of the conventional risk
assessment approaches are known to underestimate the
CV risk in Indians and are therefore not applicable.
 Pharmacokinetics of the different lipid-lowering agents
may differ in Indians with potential implications on the
optimum dosages required to achieve the lowest risk-
benefit ratio.
 There are several cultural and socioeconomic differences
that further complicate the situation. The Indian society
is primarily “food centric” with food being one of the
most important elements of any celebration. A wide va-
riety of cuisines are consumed across different states of
our country. Most of them involve extensive use of
different types of saturated fats, trans-fatty acids and
sugars. North India extensively uses saturated fats like
ghee and butter whereas the southern part traditionally
uses coconut oil as the predominant cooking medium.
Both have been shown to be highly atherogenic through
their impact on lipid levels. Also, reheating of oils for
deep frying foods is a common practice. This increases
the levels of trans-fatty acids in the food which have
incremental harmful effect on lipid levels. Sweets
consumed in large quantities during celebrations and
social gathering are also rich in dairy fats. The harmful
effects of these unhealthy eating practices are further
reinforced by the lack of physical activity among Indians,
which is becoming increasingly common as a result of
urbanization and growing affluence.
 Periodic health checks are uncommon, making timely
detection of dyslipidemia difficult. Even when detected,
treatment rates are dismal, partly because the treatment
costs are borne largely out-of-pocket. The Prospective
Urban Rural Epidemiological (PURE) study demonstrated
that only about 2.6% of CVD patients take regular medi-
cations among low income countries, including India.4
 Finally, the differences are apparent even at the health
policy level. As the burden of communicable diseases is
still substantial in our country, the primary focus of the
healthcare policies continues to remain on the communi-
cable diseases.
The present document has therefore been prepared as an
attempt to address the above concerns and to suggest man-
agement approaches that are more pertinent to Indians. It
must be remembered that this document only represents a
consensus of expert opinions, reached after a systematic re-
view of the available current scientific evidence, and is
intended primarily to assist in clinical-decision making.
However,the final decision regarding care of a particular pa-
tient has to be made by the treating physician, keeping in
consideration all relevant clinical and non-clinical factors
related to that particular patient.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S3While formulating these recommendations, the consensus
committee faced several challenges, some of which merit
attention. The biggest challenge faced was the unavailability
of large-scale epidemiological studies and outcome studies to
define normal lipid values and their relationship with the
development of CVD. Most published studies from India are
from special regional groups, which, by design, are not
representative of the entire Indian population. A large cross
sectional study, with samples from different socioeconomic
strata across different cultural groups with different dietary
habits is required to determine normal lipid values amongst
Indians. Similarly, in absence of prospective studies, it was
not possible to specifically determine the long-term impact of
different lipid management approaches in Indian subjects.
Another major hurdle in lipid management in India has been
the frequent use of non-standardized laboratories by physi-
cians across the country, not only for managing their patients
but also while reporting their experiences. Nevertheless,
despite these limitations, an attempt has been made to
transform the knowledge gained from the research conducted
so far and the clinical experience accumulated over the years
in to practical guidelines that are likely to be more relevant,
than the existing ones, to Indian populations. The available
scientific evidence relating to the different aspects of dyslipi-
demia in Indians was reviewed and compared with the data
available for the western populations. The existing western
guidelines were then modified in light of these findings to
render them more applicable to our population. If, for any
particular aspect, negligible or only limited information was
available for Indian subjects, the recommendations were
made based on the clinical practice experience of the expert
consensus group, while highlighting the limitations of such an
approach.
1.1. Governmental emphasis on public health
The government should promote a positive attitude towards
health, being proactive rather than being reactive, especially
towards CV health. As prevention is perhaps the only cure,
educating the general public about the importance of lipids
and CVD prevention should be high on the agenda. The laws
regarding permissible levels of quality and quantity of salts
and fats in packaged and restaurant foods have to be formu-
lated and strictly adhered to. Similarly, a uniform lipid testing
and monitoring strategy should be a part of National Health
Advisory statement. In addition, better urban planning and
school-based and worksite interventions for increasing
physical activity are also desirable. At the same time, the
policy initiatives should also focus on improvement in socio-
economic status and literacy, adequate healthcare financing
and public health insurance to ensure uniform availability of
healthcare to all segments of the society, irrespective of their
socioeconomic status.
Prevention of CVD in India requires concentrated efforts
from all the different sections of the society, including general
public, patient groups, doctors, media, policy makers, etc. To
be able to derive the maximum benefit, the goal should be to
influence as large section of the society as possible. Geoffrey
Rose, who developed concept of continuum of risk associated
for CVD, famously pointed out that “more people makingsmall changes in their risk factor profile are likely to result in a
much larger benefit to the society, as opposed to large changes
in a small number of patients”.52. Epidemiological aspects
2.1. Burden of CVD in India
CVDs are the largest causes of mortality in the world and
majority of deaths occur in low and middle income countries
such as India.6 The Global Burden of Diseases (GBD) Study
2010 reported that coronary heart disease (CHD) and stroke
are the top 2 causes of deaths globally. From years 1990e2010,
mortality from these diseases has increased by 35% for CHD
and 26% for stroke.7 In terms of global years of life lost (YLL),
CHD and stroke were at number 4 and 5 in global ranking in
1990 but have since jumped to rank 1 and 3 in 2010.3 In South
Asia (India), CHD is at number 4 and stroke is at 9 for YLLs,
with lower respiratory infections, preterm birth complica-
tions, diarrheal diseases, chronic obstructive pulmonary dis-
ease, sepsis, neonatal encephalopathy and tuberculosis being
the other leading causes of YLLs.7
CV mortality rates in India are quite high and are among
the highest in the world. WHO reports annual age-adjusted
mortality rate in men and women respectively of 386 and
283/100,000.6 These rates are similar to those in other South
Asian countries and much greater than in USA (men 191,
women 122/100,000) and all European countries except
Russia.6 Only a few prospective studies of CV mortality are
available. A small study in rural Gujarat8 and a larger study in
rural Andhra Pradesh9 reported age-adjusted annual mortal-
ity rates of 200e250/100,000 while studies in urban Kerala10
and Mumbai11 have reported high CV mortality rates
approaching 500/100,000 for men and 250/100,000 for women.
These rates are almost twice that of USA and 3e5 times
greater than many European countries.6
In the last 50 years there have been multiple CV epidemi-
ological studies in India that have defined prevalence of CHD
and stroke and identified burden of disease.12 Ameta-analysis
of these studies reported that prevalence rates have more
than trebled in the Indian population.13 Studies in middle of
last century reported a low prevalence of 1e2% in urban lo-
cations and 0.5e1% in rural locations with very little urban-
rural difference. In the intervening years the CHD preva-
lence in urban areas increased to 10e12%while it increased to
only 4e5% in rural adults.12 However, using the criteria of
known CHD or pathological ECG-Q waves a lower prevalence
has been reported in various Indian studies. The PURE Study
reported prevalence of known CHD, stroke or either in high
income, upper middle income, lower middle income and low
income (mainly India) countries. The prevalence (%) of CHD
was 4.2, 3.2, 4.8 and 2.1, stroke 1.3, 1.6, 1.7 and 1.0, and either of
the two 5.2, 4.5, 6.1 and 3.0 percent, respectively.4
2.2. CV risk factors
There are no prospective CV epidemiological studies that have
identified risk factors of importance in India. However, mul-
tiple case-control studies exist.3,12 The largest of these case-
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performed in 15152 cases with acute MI and 14820 controls in
52 countries of the world. About 4000 cases (n ¼ 1732) and
controls (n ¼ 2204) were from the South Asian region.14 This
study showed that 9 standard risk factors including smoking,
abnormal lipids, hypertension, diabetes, high waist-hip ratio,
sedentary lifestyle, psychosocial stress, and lack of con-
sumption of fruits and vegetables explainedmore than 90% of
acute CHD events in South Asians (Table 1). These risk factors
were similar to those in other populations but developed at a
younger age in South Asians, which explained the earlier
onset of disease in them.14 Similarly, the INTERSTROKE
study15 also reported that ten common risk factors explained
more than 90% of the incident haemorrhagic and thrombotic
strokes. The risk factors were same as in the INTERHEART
study (apart from cardiac illnesses being an additional cause
of strokes) but the population attributable risks were different
with greater importance of hypertension and lesser impor-
tance of diabetes and lipids (Table 1).
Although, in the INTERHEART study, overall contribution
of the common risk factors was same in South Asians as in
other regions, there were some important variations. Some of
the harmful factors [elevated Apo B100/Apo A-1 (Apo B100/Apo
A-1) ratio and history of diabetes] were more common in
South Asians than in individuals from other countries (43.8%
vs 31.8% and 9.5% vs 7.2%, respectively) whereas some pro-
tective factors were lower in South Asian controls as
compared to controls from other countries (moderate or high
intensity exercise 6.1% vs 21.6% and daily intake of fruits and
vegetables 26.5% vs 45.2%, p < 0.001).14
2.2.1. Risk factor prevalence and trends
Review of epidemiological studies suggests that all the major
CV risk factors are increasing in India. Tobacco production
and consumption have increased significantly. Smoking is
increasing particularly in the low educational stratum in the
urban areas16 and among younger subjects (20e35 years).17
Prevalence of hypertension has increased in both urban and
rural subjects and presently is 25e40% in urban and 10e15%
among rural adults.18,19Although there are large regional
variations in prevalence of diabetes, it has more thanTable 1 e Population attributable risks (%) of various
cardiovascular risk factors in INTERHEART and
INTERSTROKE studies (Data source: Yusuf S, et al3 and
O'Donnell M, et al15).
Risk factor INTERHEART
(acute myocardial
infarction)
INTERSTROKE
(any stroke-
thrombotic,
haemorrhagic)
Apo A/B ratio 49.2 24.9
Hypertension 17.9 (history) 34.6
Smoking 35.7 18.9
Diabetes history 9.9 5.0
High waist-hip ratio 20.1 26.5
Psychosocial stress 32.5 9.8
Regular physical activity 12.2 28.5
Diet/high poor diet score 13.7 18.8
Lack of alcohol intake 6.7 3.8
Cardiac causes e 6.7quadrupled in the last 20 years, from <1 to 3% to 10e15% in
urban and 3e5% in rural areas.20 The current prevalence rates
of diabetes are significantly greater in India as compared to
most high and middle income countries.20,21 Only China and
the middle-eastern countries have greater diabetes preva-
lence.21 Similarly, studies have reported an increase in obesity
also, esp. the more ominous truncal obesity.22 The prevalence
of dyslipidemia has also increased, as discussed in the sub-
sequent sections.
Unfortunately, most of the data presented above have
come from multiple cross-sectional studies and there are
almost no studies that have evaluated risk factors using a
prospective cohort design. The only studies to come closest to
a prospective design have been a series of five Jaipur Heart
Watch studies that evaluatedmultiple CV risk factors in urban
middle-class subjects using multiple cross-sectional study
design over a period of twenty years from 1991e2010.23 Over
this period, in these urban subjects, the prevalence of smoking
declined, hypertension did not change significantly, while
cardiometabolic risk factors such as obesity, truncal obesity,
hypercholesterolemia, diabetes and metabolic syndrome
increased significantly.
The prevalence of CV risk factors in India has significant
regional variations also.24 The second and third National
Family Health Survey (NFHS) reported state-wise prevalence
of smoking and obesity in Indians.25 The smoking rates were
the highest in eastern Indian states and the lowest in Punjab
whereas the prevalence of overweight and obesity was the
highest in southern and northern Indian states and the lowest
in central Indian states.22 Although regional variations in
other CV risk factors are not well reported within a single
study using uniform methodology, review of hypertension
epidemiological studies shows that the prevalence of hyper-
tension is significantly greater in metropolitan cities such as
Mumbai and low in less populated cities.18,19 However, these
same studies have also shown thatthe hypertension preva-
lence in rural populations is approaching the rates in urban
subjects. The studies for hypercholesterolemia have not
shown a very large regional variation (Table 2), but the prev-
alence is significantly greater in urban as compared to rural
populations.26 The ICMR-WHO six-site CV risk factor surveil-
lance study reported hypercholesterolemia (200 mg/dl) in
urban, peri-urban and rural sites in 31.7, 18.1 and 19.5% men
and 32.8, 23.4 and 26.4% women respectively (p < 0.01 for
urban-rural difference).27 These prevalence rates are lower
than in high and middle income countries.28
2.3. Dyslipidemia prevalence, patterns and
determinants
The termdyslipidemia is used to denote the presence of any of
the following abnormalities, occurring alone or in
combination-increased concentration of TC or LDL-Cor serum
TG or a decreased concentration of HDL-C.
Although it is difficult to compare observations from
different studies due to different cut-offs taken to define
dyslipidemia, different sampling procedures and different
methodologies used for estimations of lipoproteins, dyslipi-
demia appears to be widely prevalent in India. The prevalence
of hypercholesterolemia (TC 200mg/dl) alone, as reported in
Table 2 e Prevalence of hypercholesterolemia
(TC ≥ 200 mg/dl) in recent Indian studies (Data source:
Maheshwari P, et al26).
Study Year
reported
Sample
size
Prevalence (%)
Men Women
Delhi Urban Slum Study 2001 532 26.8 27.5
Jaipur Heart Watch-2 2002 1123 34.1 36.1
Chennai Urban
Population Study
2003 1262 25.7 e
Indian Industrial
Population Surveillance
Study
2007 10,442 25.1 e
India Migration
Study: Rural
2010 1983 21.1 27.8
WHO-ICMR Integrated
Disease Surveillance
Project: Urban
2010 15,223 31.7 32.8
WHO-ICMR Integrated
Disease Surveillance
Project: Rural
2010 13,517 19.5 26.4
WHO-ICMR Integrated
Disease Surveillance
Project: Periurban/
Urban Slum
2010 15,751 18.1 23.4
Indian Women's Health
Study: Urban
2011 2008 e 27.7
Indian Women's Health
Study: Rural
2011 2616 e 13.5
Jaipur Heart Watch-3-5 2012 1941 28.9 25.6
India Heart Watch 2013 6123 25.1 24.9
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35% (Table 2). However, what is more important is the pattern
of dyslipidemia. When compared with the western pop-
ulations, Indians and migrant Asian Indians tend to have
higher triglycriede levels and lower HDL-C levels.29e37 In
contrast, mean serum cholesterol levels among Asian Indians
have been shown to be similar to that of the general popula-
tion in the US and lower than the levels in the UK.38,39 The low
HDL-C levels and hypertriglyceridemia are metabolically
interlinked and their combination has been termed as
“atherogenic dyslipidemia”, which is also characterized by
increased levels of small-dense LDL particles with relatively
normal total LDL-C, and insulin resistance.40,41 Atherogenic
dyslipidemia is particularly common in South Asians and has
been shown to have a strong association with type 2 diabetes
mellitus, metabolic syndrome and CVD.41,42
Numeorus studies have reported prevalence of different
forms of lipid abnormalities among Indians. In a randomized
sample of 13,414 adults in the age group 25e64 years living in
urban Delhi, hypertriglyceridemia was found in 73% of the
obese and 61% of the non-obese individuals.43 In another
more recent study from urban New Delhi, hyper-
triglyceridemia was observed in 42.7% individuals.44 Studies
from rural populations have shown lower prevalence of
hypertriglyceridemia but the rates are still higher than the
comparable data from the Caucasians.29 HDL-C levels are
particularly lower in Indians than in white Caucasians, as
shown consistently in several comparative studies.29e37 In
the afore-mentioned study from urban NewDelhi, lowHDL-C
was found in 37% of the study population.44 In yet anotherstudy involving ~2700 young office executives (mean age 40
years) from New Delhi, low HDL-C was found in 39.5% in-
dividuals.45 The prevalence of dyslipidemia, esp. low HDL-C,
has been shown to be unusually high among patients un-
dergoing coronary artery bypass surgery. In a cross sectional
study on 1000 such consecutive patients, dyslipidemia was
observed in 84.5% men and 93.9% women with high LDL-C
levels in 23.3% patients, elevated TG in 37.0% and low HDL-
C in 72.5% patients.46 Furthermore, it appears that average
HDL-C concentrations in all Asian subgroups whether
residing in India or elsewhere are lower than Caucasians. For
example, according to Tai et al ~34% of the subjects with
isolated low HDL-C levels in the multi-ethnic population in
Singapore were Asian Indians.47 Finally, studies have also
documented significantly higher prevalence of atherogenic
small, dense LDL-Cin Indians as compared to the white
Caucasians.48
Not only the prevalence of dyslipidemia is high among
Indians, it has been increasing steadily over the past few de-
cades. The serial Jaipur Heart Watch studies have demon-
strated progressive increase in the mean levels of TC, LDL-C
and non-HDL-C and a decline in the HDL-C levels. The tri-
glyceride levels, however, have not increased and in fact have
shown a decline during the same period.49
The relative importance of different lipid components in
causation of CVD in different ethnic groupswas highlighted in
the INTERHEART study (Table 3). Overall, Apo A-1 was a better
marker of protection (odds ratio, OR, 0.72, CI 0.66e0.78) than
HDL-C (OR 0.97, CI 0.90e1.05) while raised Apo B100/Apo A-1
was the best indicator of risk.50 Importantly, the risks asso-
ciatedwith 1 S.D. change in TC, non-HDL-C, Apo B100, TC/HDL-
C and Apo B100/Apo A-1 in South Asians were similar to those
in other ethnic groups.
2.3.1. Reasons for greater prevalence of atherogenic
dyslipidemia in Indians
The higher prevalence of atherogenic dyslipidemia in Indians
can be attributed to environmental as well as genetic factors-
2.3.1.1. Environmental factors. Changing socioeconomic ar-
chitecture of the society has resulted in a multitude of life-
style abnormalities that appear to be contributing to the
development of CV risk factors and CVD in India. The role of
environmental factors in the development of CVRFs has been
highlighted by the migrant studies comparing Indian subjects
living in India with those living in other countries and with
other ethnic groups. For example, Bhatnagar et al compared
coronary risk factors in a randomly selected group of 247
migrants from the Indian subcontinent of Punjabi origin living
inWest London and 117 of their siblings living in the Punjab in
India.51 The West London cohort had a greater body mass
index, systolic blood pressure, serum cholesterol, Apo B, lower
HDL-C and higher fasting blood glucose than their siblings in
the Punjab (p < 0.01). Insulin sensitivity was lower in men in
West London than in their counterparts in India (p < 0.05).
Similar results have been reported by other migrant studies
also which have shown greater prevalence of truncal obesity,
metabolic syndrome and diabetes among Indian subjects than
other ethnic groups. More importantly, these studies have
also shown that unhealthy lifestyle practices and not
Table 3 e Risk of acute myocardial infarction with 1 SD change in various lipid measures in INTERHEART study (Data
source: McQueen MJ, et al50).
South Asians European Chinese Latin American Overall
TC 1.23 (1.14e1.31) 1.08 (1.02e1.15) 1.16 (1.09e1.23) 1.05 (0.97e1.14) 1.16 (1.13e1.19)
HDL-C 0.97 (0.90e1.05) 0.78 (0.73e0.83) 0.83 (0.78e0.88) 1.03 (0.94e1.13) 0.85 (0.83e0.88)
Non-HDL-C 1.23 (1.15e1.31) 1.17 (1.10e1.24) 1.24 (1.18e1.31) 1.04 (0.96e1.28) 1.21 (1.17e1.24)
Apo A-1 0.72 (0.66e0.78) 0.70 (0.66e0.75) 0.67 (0.63e0.71) 0.67 (0.61e0.74) 0.67 (0.65e0.70)
Apo B 1.38 (1.29e1.48) 1.24 (1.16e1.32) 1.28 (1.20e1.36) 1.18 (1.09e1.28) 1.32 (1.28e1.36)
TC:HDL-C 1.10 (1.04e1.17) 1.31 (1.21e1.42) 1.34 (1.24e1.45) 0.97 (0.90e1.05) 1.17 (1.13e1.20)
Apo B/ApoA-1 1.53 (1.42e1.64) 1.47 (1.37e1.59) 1.77 (1.63e1.92) 1.27 (1.17e1.38) 1.59 (1.52e1.64)
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diometabolic risk factors among Indian migrants.52
Common socioeconomic/behavioral/cultural changes that
underlie the increasing prevalence of CVRFs and CVD in India
include-
 Nutritional Transition: With better purchasing power,
South Asians are increasingly consuming diets high in
saturated fats, cholesterol, and refined carbohydrates and
low in polyunsaturated fatty acids and fiber.53 Impor-
tantly, while processed non-traditional ‘fast-foods’
contribute to faulty diets, some of the locally made ‘fast-
foods’ sold by street vendors in several developing coun-
tries are equally unhealthy. These food items contain high
amount of trans-fatty acids due to deep-frying using low
cost and widely available partially hydrogenated vege-
table oils.53,54
 Urbanization and demographic transition: In South Asia,
urbanization is increasing rapidly and has now encom-
passed nearly 38% of the population and is expected to
increase to 50% by 2020. Urbanization exposes people to a
number of challenges such as imbalanced diets, physical
inactivity, long working hours and other urban stresses,
making them vulnerable to CVD.
 Migration: Migration, whether inter-country or rural-to-
urban within country, is a risk factor for T2DM and CVD.
In an earlier study, it was shown that migrant post-
menopausal women settled in urban slums had high
prevalence of multiple CVD risk factors.55 These findings
were further supported by a later study from the same
group that showed a distinct gradient in the prevalence of
cardiometabolic risk factors between rural, rural-urban
migrants and urban residents.56
 Physical inactivity: The changes of occupations, advent of
newer technologies and rapid pace of urban life have
increasingly resulted in more sedentary work and less
energy expenditure. Other social factors for physical inac-
tivity include priority for academics at the cost of playing
time in children, increasing use of television and com-
puters, lack of playfields and open spaces, and security
concerns in the outdoors, especially for women. In a study
involving different ethnic groups, lower level of physical
activity in Asian Indians, Pakistanis and Bangladeshis was
seen to be inversely correlated with body-mass index,
waist circumference, systolic blood pressure, plasma
glucose and insulin levels.57
 Other socio-economic and cultural factors: Socio-cultural
and psychological factors and prevalent misconceptionsare important factors to be looked at formodifying diet and
lifestyle habits in India. In this region, there is a prevalent
misconception that an ‘obese child is a healthy child’ and,
hence should be fed in excess. Mothers often have tradi-
tional belief that feeding excess ghee (clarified butter) and
butter to children would be beneficial for their growth and
impart them strength. A cross-sectional study of 1800
children aged 9e18 years and their mothers, using quali-
tative (focus group) and quantitative (semi-structured
survey) data, showed such widely prevalent myths, and
correlation between obesity and dietary habits of children
and their mothers.58
2.3.1.2. Genetic factors. Genetic susceptibility of Asian Indians
to development of dyslipidemia and obesity has been shown
in some studies. Association of Apo B gene polymorphisms
(Xba I and EcoRI) with hyperlipidemia has been reported in
migrant Asian Indians.59,60 Similalry, positive correlation has
also been reported between Apo E3/E3 phenotype and low
levels of HDL-C.61 In another study conducted in north India,
APOC3 SstI gene polymorphism (S1S1, S1S2 and S2S2 geno-
types) was shown to be associated with plasma triglyceride
levels.62 It is notable that the polymorphisms of the APOC3
promoter (455 T/C and 482C/T) are frequently encountered
in young migrant Asian Indians.63
Another study reported that variants of Myostatin gene
predispose to obesity, abdominal obesity and low lean body
mass in north Indians.64 In yet another study, LMNA 1908T/T
and C/T genotypes were found to be the independent risk
factors for generalized obesity in non-diabetics.65 And finally,
a recent study has shown DOK5 as a susceptibility gene for
obesity and T2DM in Indians.66 All these studies are small and
inconclusive. Larger studies are required.3. Evaluation of a patient with dyslipidemia
3.1. Measurement of lipid values
Measurement of lipids is the first step towards management
of dyslipidemia. The NECP-ATP III guidelines recommend
that a lipid profile should be obtained at least once every 5
years in adults age 20 years or above.67 However, consid-
ering the issues of applicability, accuracy and costs involved
in India, the present consensus committee recom-
mendsperforming lipid estimations as a routine in adults
above 30 years of age. In patients younger than 30 years, the
need to perform a lipid estimation should be individualized,
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tors and evidence of pre-existing CVD. This recommenda-
tion of higher age-threshold for initial lipid estimation is
commensurate with that of the European Society of Cardi-
ology/European Atherosclerosis Society (recommend
screening in adult men 40 years of age, and in women 50
years of age).68 After initial lipid profile measurement, the
timing and frequency of subsequent testing should be
determined by the abnormalities detected in the initial
assessment and can vary from once every five years to as
frequent as every 6e12 weeks.
A typical lipid profile consists of TG, TC, HDL-C and LDL-C.
Most of the laboratories measure TC, TG and HDL-C directly
using enzymatic assays but LDL-Cis often derived indirectly
from the Friedewald equation (LDL-C ¼ TC-HDL-C e TG/5). As
feeding acutely affects serum TG levels, a fasting blood sam-
ple (after 9e12 h fasting) is required to estimate LDL-C accu-
rately. This presents a practical challenge as many-a-times
circumstances do not allow fasting sampling. In such settings,
using non-HDL-C instead of LDL-Cis a good alternative. Non-
HDL-C is calculated simply by subtracting HDL-C from TC
and because food does not affect TC or HDL-C acutely, non-
HDL-C remains accurate irrespective of fasting status. As
discussed subsequently, non-HDL-C has several additional
advantages over LDL-C as a CV risk marker. It includes all the
atherogenic lipid molecules present within the blood such as
VLDL, intermediate density lipoprotein (IDL), chylomicrons,
chylomicron remnants and lipoprotein (a) [Lp(a)] and there-
fore provides a more accurate estimate of CV risk than LDL-C
alone, as shown in numerous epidemiological and clinical
studies.69e73 This is particularly true for patients who are
already on statin therapy74 or those with elevated levels of
VLDL-C such as patients with obesity, metabolic syndrome
and diabetes.
Some prospective studies have reported that non-fasting
serum triglyceride levels may be a useful predictor of CV
events.75 However, issues such as standardizing sampling
conditions and reference values are yet to be clarified.
Routine estimation of Apo B and Apo A-1 levels is not
recommended at present because of several logistic issues.
These assays are expensive, not readily available, and not
adequately standardized. Moreover, non-HDL-C, by incorpo-
rating all Apo B containing lipid particles in blood, can provide
a similar, albeit slightly less accurate, information in a more
cost-effective and simpler manner.
Summary
The present consensus committee recommends that lipid
measurement should be performed in all adults beginning at
the age of 30 years. As all the currently existing guidelines are
based on LDL-C levels, it is advisable to obtain complete
fasting lipid profile. However, when fasting sample cannot be
obtained, measurement of TC, HDL-C and non-HDL-C from a
non-fasting sample should be sufficient and if required, a
more detailed lipid profile can then be obtained in selected
individuals. Routine measurement of Apo B and Apo A is not
recommended at present.
After the initial screening, the nature, frequency and
timing of subsequent testing should be determined based on
the findings on the initial assessment.3.2. CV risk stratification
3.2.1. Assessment of the absolute CV risk: role of risk
assessment algorithms
Traditionally, assessment of the CV risk is performed by
determining the presence and severity of the major CV risk
factors and subsequently using risk algorithms and prediction
charts to determine the overall CV risk in any given individual.
A number of risk assessment tools are available for this pur-
pose such as Framingham risk score (FRS),76,77 Prospective
Cardiovascular Munster Score (PROCAM),78 World Health Or-
ganization/International Society of Hypertension (WHO/ISH)
CVD risk prediction charts,79 Joint British Societies for CVD
risk chart,80 Systemic Coronary Risk Evaluation (SCORE),81
QRISK,82e84 Reynolds score,85,86 New Zealand score,87 etc.
Among them, FRS is themost commonly used risk assessment
algorithm in clinical practice.
3.2.1.1. FRS: the most commonly used CV risk assessment al-
gorithm. The FRS is based on the data derived from the Fra-
minghamHeart Studywhichwas initiated in1948 in the townof
Framingham inMassachusetts, USA. The initial FRS, whichwas
developed in 1998, predicted only coronary heart disease (CHD)
risk but subsequently, a new general risk prediction tool was
developed in 2008 to predict the overall CVD risk.76,77 The FRS is
based on age, gender, smoking status, diabetes, systolic blood
pressure (SBP), total or LDL-C and HDL-C. Based on these pa-
rameters, an individual's 10-year absolute risk of adverse CHD
or CVD events is estimated. Ten-year risk <10% signifies low
risk, 10e20% intermediate risk and >20% indicates high risk.
While FRS has been validated in a number of populations
and has been the cornerstone of CV risk assessment over the
years, it has several limitations.88 First, it was developed at a
time when the CVD incidence was at its peak in the US. As a
result, FRS tends to overestimate CV risk in populations in
which the CVD incidence is much lower, as in the Europeans.
Second, FRS does not take in to account many of the non-
conventional risk factors such as obesity, physical activity,
family history of premature CAD, etc which are being
increasingly recognized as important contributors to the
development of atherosclerotic vascular disease. Finally, FRS
relies heavily on age as a determinant of the CV risk. Conse-
quently, in a young individual, the estimated 10-year CV risk
according to FRS is invariably low, despite the presence of
multiple CV risk factors. This has important implications for
Indians inwhomCVD tends to occur at a younger age than the
western populations. As a result, FRS is likely to underesti-
mate CV risk in Indians, as has been amply highlighted in
some of the studies.89,90
3.2.1.2. Alternate CV risk scores. A number of other scoring
systems, as mentioned above, have been developed to over-
come the limitations of FRS but none of them has been vali-
dated in Indians.
In 2007, the World Health Organization (WHO), in collabo-
ration with the International Society for Hypertension (ISH),
published a series of risk prediction charts, each dedicated to a
different geographic region, including South-East Asia79
(Fig. 1). These risk assessment charts have been derived with
the help of statistical models using extrapolated data about
Fig. 1 eWorld Health Organization cardiovascular risk prediction charts applicable for Indians (South-East Asia Region D).
These charts predict 10-year risk of a fatal or non-fatal cardiovascular event.
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geographical regions. Though these charts have not been
systematically validated in prospective studies, this scoring
system is among the very few that specifically refer to the
South Asian populations.
More recently, two new risk scoring systems have become
available. The American College of Cardiology/American
Heart Association (ACC/AHA) task force on practice guidelines
in 2013 developed a new risk assessment approach using
pooled data frommultiple cohorts, including the Framingham
original and off-springs cohorts.91 However, this score has
also not been validated in Indians and its accuracy, even for
Americans, has become a subject of controversy.92,93 At the
same time, the 3rd iteration of the Joint British Societies (JBS)
have also come out with their own risk assessment model.94
Although this risk score is applicable to the populations in
the UK, it includes data on non-resident Indians also andmay
therefore be able to provide relatively more accurate risk es-
timates for resident Indians than other risk algorithms.339
A yet another approach, as has been suggested by several
investigators, is to recalibrate the FRS by multiplying the
calculated FRS by a correction factor, specifically derived for agiven population. For rural Indians, the suggested correction
factor is 1.0 for men and 0.8 for women, whereas the same for
urban Indians is 1.81 and 1.54 for men and women
respectively.
Summary. Estimation of the future CV risk is an essential
prerequisite for defining optimum lipid-lowering strategy
(pharmacological and non-pharmacological) in any patient
with dyslipidemia. Unfortunately, none of the currently
available risk scoring algorithms have been specifically vali-
dated in Indians. However, of all the available options, the
WHO/ISH risk prediction charts and the JBS3 risk prediction
model may be more relevant to the Indians (Fig. 1).
3.2.2. Role of sub-clinical atherosclerosis imaging
The conventional risk assessment algorithms have yet
another important limitation thatwhile they work well at the
population level, their accuracy at the individual level is
limited. Thus, it is not uncommon to find individuals with no
apparent CV risk factors to develop CVD while many of those
with multiple CV risk factors remain free from CVD for years.
Accordingly, one of the major challenges to CVD prevention is
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actually going to develop the disease. A potential solution to
this problem is to look for the evidence of the disease itself,
when it is still in its subclinical stage, rather than the risk
factors. If a person has evidence of sub-clinical atheroscle-
rosis, he or she has high probability of developing clinically
manifest CVD later on, irrespective of the presence or absence
of the CV risk factors and will therefore deserve aggressive
risk factor modification. Several tools for detection of sub-
clinical atherosclerosis are now available such as carotid
plaque assessment, carotid intima-media thickness (CIMT),
brachial artery flow-mediated dilatation, coronary calcium
score (CCS), ankle-brachial index, pulse wave velocity, etc.
Among them, carotid imaging and CCS appear to be the most
promising and have an extensive evidence-base to support
their use in clinical practice.
Carotid ultrasound imaging allows detection and charac-
terization of carotid plaques andmeasurement of CIMT. CIMT
refers to the combined thickness of intima and media of the
carotid arteries, usually measured at the distal common ca-
rotid artery. The basic premise underlying carotid vascular
imaging is that atherosclerosis is a generalized process, which
affects all vascular beds sooner or later. Hence, the evidence of
atherosclerosis in carotid arteries is likely to indicate high risk
of coronary events also. This hypothesis has been adequately
validated in autopsy studies as well as a number of large
clinical trials.95
CCS is a computed tomography test that detects and
quantifies the amount of calcium in the coronary arteries. In
coronary arteries, calcium is deposited only in the athero-
sclerotic plaques and therefore the presence of coronary cal-
cium serves as an indirect evidence of ongoing atherosclerotic
process in the coronary arteries. The total CCS is directly
related to the total atherosclerotic burden in the coronaries
and has an excellent correlation with the risk of adverse CV
events. However, the calcium in the coronaries is not site-
specific, i.e. the site of maximum calcium deposition may
not necessarily be the site of the most significant luminal
narrowing. This occurs as a result of positive remodeling in
which the coronary arterial wall undergoes expansion sec-
ondary to inflammation produced by the atherosclerotic pro-
cess. The CCS estimation involves radiation exposure but does
not require the use of iodinated contrast medium.96
Numerous clinical trials involving several thousand pa-
tients have shown that both carotid atherosclerosis and CCS
have incremental value above conventional risk factors and
the risk assessment algorithms such as FRS in predicting
future risk of CV events.95e97 Using these tools permit esti-
mation of the vascular age of the patients which provides the
clinician and the patient with a simple, easily understandable
assessment of the overall vascular health of the individual.
Themain incremental role of these tools is in patients deemed
to be at intermediate risk. The treatment can be intensified in
those who are shown to have the evidence of ongoing
atherosclerosis whereas a less aggressive approach can be
adopted in those having no evidence of atherosclerosis. An
added advantage of these imaging techniques is that theymay
also help in improving patient compliance to the treatment.
The patients, when shown the evidence of ongoing athero-
sclerosis, are more likely to adopt healthy life-style measuresand are more likely to follow the pharmacological
advices.9,98e102
3.2.2.1. Experience with subclinical atherosclerosis assessment
in Indians. Several cross-sectional studies have been per-
formed in resident Indians to assess the utility of CIMT and
CCS in them. CIMT has been shown to correlate with the
presence and extent of existing CAD as well as the presence of
conventional CV risk factors.103e111 However, no prospective
study demonstrating utility of CIMT is available in Indian
subjects. In addition, the normal reference values of CIMT in
Indian subjects are also not available at present. The datawith
CCS is evenmore limitedwith hardly few studies published so
far.112,113 These limitations preclude routine clinical use of
CIMT or CCS for CV risk stratification in Indians.
Summary. The assessment of subclinical atherosclerosis
is an attractive approach to refine CV risk estimate in pa-
tients considered to be at ‘intermediate risk’ on the basis of
the conventional risk assessment methods. However, their
routine use cannot be recommended at present because of
the lack of outcome data with these techniques and also
because the normal reference values for these various
atherosclerosis markers are not yet available for Indians.
Nevertheless, the physicians or cardiologists with adequate
experience with these techniques may continue to use them
to more accurately define the CV risk in appropriate patient
subgroups.
3.2.3. Biochemical markers for risk assessment
Atherosclerosis is now well-recognized to be an inflamma-
tory disease. Consequently, a number of markers of
inflammation have been shown to be associated with the
extent of atherosclerosis and the risk of adverse CV events.
Among them, high-sensitive c-reactive protein (hsCRP) has
been the most extensively studied marker.114e118 Several
large-scale prospective studies have shown that elevated
hsCRP levels strongly predict the risk of CV events and may
be a target for initiation of statin therapy, irrespective of the
lipid levels.118 Based on the available evidence, the AHA
recommends that in men 50 years or women 60 years
with LDL-C less than 130 mg/dl, measurement of hsCRP can
be useful in the selection of patients for statin therapy in
absence of any other inflammatory condition or contrain-
dications to statins.97 However, a major drawback with
hsCRP is that it is a marker of inflammation and not
atherosclerosis per se. Therefore, any significant inflam-
matory condition can lead to the elevation of hsCRP levels
and hence adequate care needs to be taken to avoid using
hsCRP as a marker of CV risk in presence of any underlying
inflammatory disease.
At present, there is only limited data available to assess the
role of hsCRP in CV risk assessment in Indians. While several
cross-sectional studies have demonstrated relationship be-
tween hsCRP and various conventional and non-conventional
CV risk factors,119e123 no prospective study is available as yet
to show the prognostic utility of hsCRP measurement in
Indians.
Lp(a) is a genetically modified form of LDL-C particle which
appears to confer higher risk of CVD owing to its ability to bind
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imparted by several other CV risk factors such as diabetes, low
HDL-C and high LDL-C.124 A number of studies have reported
an association between Lp (a) levels and incident CVD.125e127
However, prospective studies have failed to conclusively
establish a causative link between Lp (a) and CVD.128e130 This,
coupled with the lack of standardized tests for accurate
measurement of Lp (a) and limited therapeutic options for
lowering it, have prevented widespread use of Lp (a) mea-
surement in clinical practice.67 Nevertheless, Lp (a) may be an
important riskmarker in Indian subjects as Indians are known
to have higher levels of Lp (a) with asmany as 30e40% Indians
having levels >20 mg/dl, which is generally considered as the
threshold for high risk for CAD.131
Summary. Routine measurement of hsCRP and Lp(a) is not
recommended at present. The use of these markers to further
refine CV risk in intermediate risk patients is optional. Lp(a)
estimation can be considered in patients with family history
of premature CAD.
3.2.4. Other markers for CV risk assessment
Urinary albumin excretion has been suggested to be a useful
tool for CV risk prediction as microalbuminuria is considered
to be a manifestation of vascular damage. The presence of
microalbuminuria not only indicates already existing vascular
damage but may also contribute to further vascular injury
through multiple mechanisms. However, the value of micro-
albuminuria as a CV risk marker is restricted largely to the
patients with diabetes or hypertension.97
3.2.5. Suggested approach to CV risk assessment in Indians
(Fig. 2, Box 1).
Fig. 1 presents a practical approach to the CV risk assessment
in Indian subjects based on the available evidence and these
recommendations are summarized in Box 1.
When a patient presents with one or more clinical features
of already existing atherosclerotic vascular disease, he or she
is considered to be at “high-risk” and no formal risk scoring is
required. Long-standing diabetes, particularly with other CV
risk factors or with evidence of target organ damage and
presence of chronic kidney disease also signify high CV risk
and should be treated accordingly. Conversely, if there is no
evidence of pre-existing atherosclerotic vascular disease and
the patient has no or only one major CV risk factor, the risk of
adverse CV events is generally low. An exception to this is
when there is an extreme of the single risk factor such as
strong family history of premature CAD, chronic heavy
smoking, markedly deranged lipid values, etc. In all the
remaining patients, formal risk scoring needs to be per-
formed. If the estimated 10-year CV risk is >20%, it signifies
‘high CV risk’, 10e20% ‘moderately high risk’ and <10% risk
indicates ‘moderate or intermediate risk’. Since majority of
the asymptomatic patients encountered in the regular clinical
practice fall in the ‘intermediate risk’ category, further
refinement of the risk estimate is required in them to permit
better matching of the intensity of the therapeutic approach
with the true CV risk. In such patients, it is advisable to look
for the presence of one or more of the non-conventional risk
factors such as- Obesity
 Sedentary lifestyle
 Metabolic syndrome
 Impaired fasting glucose or impaired glucose tolerance
 Raised levels of C-reactive protein, homocysteine, or Lp(a)
 Microalbuminuria
 Psychosocial stress, etc.
If a combination of the above risk factors is present in a
patient otherwise deemed to be at intermediate risk, it will
signify higher CV risk warranting more aggressive risk
reduction strategy. However, if none of the above risk factors
is present and the estimated 10-year risk is <10%, the patient
can be safely treated as ‘low-risk’.
When available, the imaging for subclinical atherosclerosis
can also be performed in patients at ‘intermediate-risk’ to
provide direct evidence of atherosclerosis and to further refine
the CV risk.4. Management of dyslipidemia
4.1. Lipid goals and overall approach to treatment
(Please also refer to Section 5 for discussion on the implica-
tions of recently published ACC/AHA guidelines on manage-
ment of dyslipidemia).
4.1.1. Primary prevention
Fig. 3 presents the overall approach to the management of
dyslipidemia.67,68 Given the extensive database demon-
strating association between LDL-C and CV risk and the
powerful beneficial effects of LDL-C reduction, LDL-C remains
the primary target for lipid lowering therapy (unless serum
triglyceride levels are very high e.g. >500 mg/dl). However, as
discussed above, when accurate LDL-C values are not avail-
able (for example in case of non-fasting sampling), non-HDL-C
is an acceptable primary target of therapy. Non-HDL-C is also
a more accurate predictor of CV risk than LDL-C in disease
statescharacterized by elevated triglyceride levels such as
metabolic syndrome and diabetes-the conditions commonly
seen among Indians.71,132 As the initial treatment approach
for lowering non-HDL-C is same as that for lowering LDL-C,
using non-HDL-C as the primary target for therapy does not
require any deviation from the standard clinical practice. At
the same time, as LDL-C is lowered with the help of statin
therapy, non-HDL-C becomes an increasingly superior pre-
dictor of residual CV risk than the on-treatment LDL-C
levels.74
In any patient requiring lipid lowering treatment for pri-
mary prevention of CVD, the management approach is
tailored according to the estimated global CV risk, based on
which the goals for lipid lowering and means of achieving it
are decided. The appropriate LDL-C goals and cut-off levels for
initiating pharmacological therapy are listed in Table 4. As
there are no prospective studies available to determine the
optimal LDL-C levels and the treatment thresholds in Indians,
these recommendations are based on the available western
guidelines only.67,68,133 The recommended non-HDL-C goal for
each category of patients is 30 mg/dl higher than the
Fig. 2 e Suggested cardiovascular risk assessment approach in Indians with dyslipidemia. * Themajor risk factors include-i)
Cigarette smoking (any cigarette smoking during the last one month), ii) Hypertension (blood pressure ≥140/90 mmHg or on
antihypertensive medication), iii) Low HDL-C cholesterol (<40 mg/dl), iv) Family history of premature CAD (CAD in male
first-degree relative <55 years or in female first-degree relative <65 years), v) Age ≥45 years in men and ≥55 years in
women). If the HDL-C cholesterol level is > 60 mg/dl, it is considered a negative risk factor CAD-coronary artery disease;
CRP- c-reactive protein, HDL-C- high-density lipoprotein cholesterol; IFG-impaired fasting glucose; IGT-impaired glucose
tolerance; ISH- International Society of Hypertension; JBS- Joint British Societies; WHO- World Health Organization.
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mendation is that non-HDL-C primarily reflects the sum total
of LDL-C and VLDL-C and 30 mg/dl cholesterol in VLDL-C
would correspond to serum triglyceride level of 150 mg/dl,
which is the acceptable upper limit of normal.
Therapeutic life style change (TLC, discussed in subse-
quent sections) is the initial step in the management of dys-
lipidemia and is indicated in all individuals, irrespective of
their LDL-C levels and even when LDL-C levels are within thedesired range. TLC forms an essential and important compo-
nent of lipid lowering therapy but requires a great deal of
motivation from the patient and his family. Therefore, it is
important that TLC is initiated by the clinician, explaining and
emphasizing its value in a detailed discussionwith the patient
and his/her family. Nutritionist's involvement often helps.
When the patient is unable to achieve desired changes in
LDL-C levels with TLC alone or when LDL-C levels are too high
at the time of initial presentation itself, pharmacological
Box 1
Cardiovascular risk categories as applicable to Indians.
High risk
 Patients with evidence of atherosclerotic vascular
disease (CAD, carotid artery disease, peripheral arterial
disease, abdominal aortic aneurysms, atherosclerotic
renal artery stenosis, etc)
 Long-standing diabetes mellitus, esp. with other CV
risk factors or with target organ damage
 Chronic kidney disease
 Extreme of a single major risk factor (e.g. strong family
history of premature CAD, chronic heavy smoking,
markedly deranged lipid profile, etc)
 Any combination of CV risk factors with estimated 10-
year risk >20%*
 Estimated 10-year risk <20%* but with evidence of
subclinical atherosclerosis or with multiple non-
conventional CV risk factors (obesity, metabolic syn-
drome, impaired fasting glucose, impaired glucose
tolerance, psychosocial stress, microalbuminuria, etc.)
Moderately highrisk (10-year risk of CV events 10e20%)
 Any combination of CV risk factors with estimated 10-
year risk 10-20%*
 Recent onset diabetes mellitus with no other major CV
risk factor and no evidence of target organ damage
Moderate or intermediaterisk (2 or more CV risk factors with
10-year risk of CV events <10%)
 Patients with >1 major CV risk factor# with estimated
10-year risk <10%* in absence of any of the above
markers of higher risk
Low-risk (<2 CV risk factors with 10-year risk of CV events
<10%)
 Patients with 0e1 major CV risk factor# in absence of
any of the above markers of higher risk
* Risk estimation based on World Health Association/
International Society of Hypertension risk factor charts
or Joint British Societies 3 risk scoring system (see text
for details).
# The major risk factors include-i) Cigarette smoking
(any cigarette smoking during the last one month), ii)
Hypertension (blood pressure 140/90 mmHg or on
antihypertensive medication), iii) Low HDL-C cholesterol
(<40 mg/dl), iv) Family history of premature CAD (CAD in
male first-degree relative <55 years or in female first-
degree relative <65 years), v) Age 45 years in men and
55 years in women). If the HDL-C cholesterol level
is > 60 mg/dl, it is considered a negative risk factor.
CAD e coronary artery disease; CV e cardiovascular;
HDL-C e high-density lipoprotein.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S12therapy needs to be instituted. Pharmacotherapy is also rec-
ommended from the beginning itself in individuals perceived
to be at high risk of CV events (Table 4). Among all the currently
available lipid lowering agents, statins have themost profound
effect on LDL-C and also have numerous pleiotopic effects thatcontribute to prevention of CVD. A large number of studies in a
wide range of patient populations have established unparal-
leled efficacy and safety of statins for CVD prevention. For
these reasons, statins are the first-line agent for LDL-C
lowering. The treatment should begin with a statin dose ex-
pected to lower LDL-C by the desired margin and the dose
should be up-titrated if the initial dose fails to achieve the
desired LDL-C reduction. If LDL-C goals cannot be achieved
evenwith themaximum tolerated dose of statins, other agents
such as fibrates, ezitimibe, etcmay be considered. However, it
must be remembered that large-scale studies have failed to
show incremental CV risk reduction with these agents.133
Once LDL-C goal is achieved with appropriate non-
pharmacological and pharmacological measures, the next
target for therapy is non-HDL-C, which primarily aims at
correcting serum triglyceride levels. Weight reduction is one
of the most effective modalities for lowering serum triglyc-
eride levels and the patient should be encouraged to increase
physical activity and adopt healthy diet. Smoking cessation is
also very helpful and should be encouraged. At the same time,
one should also diligently look for and correct any secondary
causes of hypertriglyceridemia if present such as uncontrolled
diabetes, nephrotic syndrome, chronic renal failure, certain
drugs (e.g. corticosteroids, protease inhibitors for HIV, beta
blockers, estrogens) etc.67,68
If the serum triglyceride levels remain high in spite of
adequate lie-stylemeasuresor if thepatient isnot able to follow
life-style measures for some reason, pharmacological mea-
suresmay be needed. Statin dose can be increased further and/
or a fibrate can be added to the regimen. It should be noted that
additionofafibrate to a statinhasbeenshown tobeofbenefit in
only select subgroup of patients (i.e. those with atherogenic
dyslipidemia)134,135 and therefore routine co-prescription of a
statin and a fibrate is neither justifiable nor recommended.
Once LDL-C and non-HDL-C goals are achieved, the next
step is to focus on HDL-C. In men, HDL-C should be above
40mg/dl and inwomen>50mg/dl. In view of the disappointing
results of the recent trials evaluating HDL-C raising therapies,
no drug can be recommended at present for correction of low
HDL-C levels and the management depends solely on TLC.
Weight reduction and smoking cessation are the two most
effective non-pharmacological measures to raise HDL-C levels
and should be aggressively pursued.67,68
4.1.2. Secondary prevention
Patients with established atherosclerotic vascular disease are
obviously at high risk of having another vascular event and
therefore deserve aggressive lipid lowering therapy. The rec-
ommended LDL-C goal in such patients is <70 mg/dl with at
least 50% reduction from the baseline value (Table 4). Given
the profound beneficial effects of statins in patients with
established vascular disease, all patients requiring secondary
prevention of CVD should be on a statin, irrespective of the
baseline LDL-C levels, while aggressive TLC is continued
simultaneously.
4.2. Life-style modifications
Lifestyle modifications including diet control, physical ex-
ercise, tobacco cessation, moderate alcohol intake and
Fig. 3 e Overall approach to lipid-lowering therapy for prevention of cardiovascular disease. (HDL-C- high-density
lipoprotein cholesterol, LDL-C- low-density lipoprotein cholesterol). * Please note, non-HDL-C is an acceptable primary
target of lipid lowering therapy if LDL-C values are not available or not reliable.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S13stress management are essential and amongst the
most cost-effective methods to control dyslipidemia and
for overall primary and secondary prevention of heart
disease.4.2.1. Diet
Dietary modification is a powerful non-pharmacological
strategy for improving blood lipids. The goals of nutrition
management are to maintain or improve quality of life,
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S14nutritional and physiological health, and to prevent and treat
dyslipidemia and associated co-morbid conditions. In general,
nutrition advice for people with dyslipidemia is the same as
that for all Asian Indians. For individuals with dyslipidemia,
attention to food portions and weight management combined
with physical activity may help improve the condition.
Nutrition in all forms of dyslipidemia management should be
individualized.
4.2.1.1. Energy. Energy intake should be limited to the
amount of energy needed to maintain (or obtain) a healthy
weight, i.e. a BMI 23 kg/m2 (Table 5). It should be enough to
support energy needs, yet allowing for a 5%e10% body-weight
loss, if indicated. Energy requirement for any individual is
calculated by multiplying the activity factor by ideal body
weight of that individual (Table 6). For example, an Asian In-
dianmanwithmediumbuilt frame, 165 cm tall, should ideally
weigh 62 kg and would require 1850 Kcal to maintain healthy
weight if he is sedentary. Ideal bodyweight should be aimed to
maintain a body mass index (BMI) between 18 and 23 kg/m2.
4.2.1.2. Carbohydrates and fiber
Recommendations
1. The daily carbohydrate intake should be approximately
50e60% of the total calorie intake. For example, in an 1800
and 2000 calorie diet, the carbohydrate intake for a
sedentary to moderately active individual should be
225e270 g/day and 250e300 g/day, respectively.
2. The primary source of complex carbohydrates in the diet
should be cereals (whole wheat, brown rice etc.), millets
[pearl millet (bajra), finger millet (ragi), great millet (Jowar)],
pulses [red gram (tur dal), green gram (sabutmoong) etc.] and
legumes [soya, horse gram (kulthi)]. Complex carbohydrates
should be preferred over refined carbohydrates and its
products, e.g. whole grain bread over white (maida) bread.
3. While deciding for carbohydrates, the glycemic index (GI)
of foods should also be considered. Emerging research,
globally and from India, has shown the relevance of GI in
the Indian context.136
4. GI is a measure of the effects of carbohydrates on blood
sugar levels. Carbohydrates that break down quickly dur-
ing digestion and release glucose rapidly into the blood-
stream have a high GI, whereas carbohydrates that break
down more slowly, releasing glucose more gradually into
the bloodstream, have a low GI. Foods having GI of 55 or
less are considered to have low GI; between 56 and 69 as
medium GI; and 70 or above as high GI. GI of some
commonly consumed foods has been provided in Table 7.
Low GI foods such as oats (jai), unpolished rice, parboiled
rice, whole pulses, beans (fali) and legumes (sabutanaz),
some whole fruits (like guava, apple etc.) should be
preferred. In contrast, high GI foods [refined flour, root
vegetables such as yam (sooran/shakarkand), potato, tapioca
(a type of shakarkand), colocasia (arbi) etc] should be
consumed in moderation.
5. Along with GI, glycemic load (GL) of the food should also be
considered, which depends on the amount of carbohydrate
consumed. The glycemic load of a food is calculated by
multiplying the GI and the amount of carbohydrate (in g)
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Table 6 e Calculation of energy requirement.
Activity level Energy requirement (Kcal/Kg IBW/day)
Obese Normal Underweight
Sedentary 20e25 30 35
Moderate 30 35 40
Heavy 35 40 45e50
Williams SR: Nutrition and Diet Therapy, 6th ed. St. Louis: Times
Mirror/Mosby, 1989.
Source: Williams, 1989
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S15provided by a food and dividing the total by 100. For one
serving of a food, a GL lower than 10 is considered low;
between 11 and 19 is consideredmedium, and 20 ormore is
considered high.
6. The total dietary fiber in daily diet should be 25e40 g/day
[e.g. 100 g of apple (1 small apple) gives 1.0 g of fiber; 100 g of
whole wheat flour gives 1.9 g of fiber]. Whole grains, ce-
reals, pulses, vegetables and fruits contain high dietary
fiber. Diets higher in soluble fiber lead to TC reductions of
5%e19% and LDL-C reductions of 8%e24%. Foods high in
soluble fiber include oat bran, oatmeal, beans, peas, rice
bran, barley, citrus fruits, strawberries, and apple pulp.
7. A minimum of four to five servings per day of fruits and
vegetables are recommended i.e. approximately 400e500 g/
day including 3 vegetable and 2 fruit portions. [e.g. 100 g
(onekatori) raw vegetables e.g. cauliflower, brinjal
etc.¼ 20e30 Kcal, 100 g fruit e.g. one apple¼ 59 Kcal]. Fruits
should be eaten whole preferably with the skin whenever
feasible instead of fruit juices.
8. Simple sugars like crystalline sugar, sugarcane juice,
sweetened carbonated beverages, fruit juices and sugar
syrups should be avoided.
4.2.1.3. Fats. A high dietary intake of fat has been reported in
Asian Indians.137,138 In a report from the National Institute of
Nutrition, fat consumption in India was documented to range
from 13 to 59 g/d in different regions and states, with rural
populations deriving smaller proportion of energy (17%) from
dietary fat as compared to urban residents (22%).139
Dietary fat includes both unsaturated and saturated fatty
acids. The substitution of unsaturated fatty acids [including
both polyunsaturated andmonounsaturated fatty acids (PUFA
and MUFA respectively)] for saturated fatty acids leads to
decreased LDL-C levels with slightly greater LDL-C reductions
observed with PUFA than with MUFA.67,140 While high intake
of PUFA may reduce HDL-C and triglyceride levels, the sub-
stitution ofMUFAfor saturated fatty acids has aminimal effect
on HDL-Cvalues and does not raise triglyceride levels.67,140e143
Consumption of trans-fatty acids is the most harmful and is
associated with both increased LDL-C and decreased HDL-
Clevels. Combined with evidence from epidemiologic cohort
studies, these effects indicate that diets high in trans-fatty
acids are associated with an increased risk of CAD; current
evidence indicates that, on a per calorie basis, risk with trans-
fatty acids is higher than with any other macro nutrients.
The ratio of n-6 and n-3 PUFA in diet is also important. Even
though it has not been well investigated in healthy in-
dividuals, long-chain n-3 supplementation clearly lowers
Table 7 e The average glycemic index of common foods derived from multiple studies by different laboratories.
High- carbohydrate
foods
GI Breakfast
cereals
GI Fruit and fruit
products
GI Vegetables GI Dairy products
and alternatives
GI Legumes GI Snack
products
GI Sugars GI
White wheat bread* 75 ± 2 Cornflakes 81 ± 6 Apple,rawy 36 ± 2 Potato, boiled 78 ± 4 Milk, full fat 39 ± 3 Chickpeas 28 ± 9 Chocolates 40 ± 3 Fructose 15 ± 4
Whole wheat/whole
meal bread
74 ± 2 Wheat flake
biscuit
69 ± 2 Orange, rawy 43 ± 3 Potato instant
mash
87 ± 3 Milk, skim 37 ± 4 Kidney
beans
24 ± 4 Popcorn 65 ± 5 Sucrose 65 ± 4
Unleavened
wheat bread
70 ± 5 Porridge,
rolled oats
55 ± 2 Banana, rawy 51 ± 3 Potato, French
fries
63 ± 5 Ice cream 51 ± 3 Lentils 32 ± 5 Potato
crisps
56 ± 3 Glucose 103 ± 3
Wheat roti 62 ± 3 Instant oat
porridge
79 ± 3 Pineapple, raw 59 ± 8 Carrots, boiled 39 ± 4 Yogurt, fruit 41 ± 2 Soya beans 16 ± 1 Soft drink/
soda
59 ± 3 Honey 61 ± 3
Chapatti 52 ± 4 Rice porridge/
congee
78 ± 9 Mango, raw 51 ± 5 Sweet potato,
boiled
63 ± 6 Soy milk 34 ± 4 Rice crackers/
crisps
87 ± 2
Corn tortilla 46 ± 4 Millet porridge 67 ± 5 Watermelony,
raw
76 ± 4 Pumpkin, boiled 64 ± 7 Rice milk 86 ± 7
White rice, boiled* 73 ± 4 Muesli 57 ± 2 Dates, raw 42 ± 4 Plantain/green
banana
55 ± 6
Brown rice, boiled 68 ± 4 Peaches,
cannedy
43 ± 5 Taro, boiled 53 ± 2
Barley 28 ± 2 Strawberry
jam/jelly
49 ± 3 Vegetable soup 48 ± 5
Sweet corn 52 ± 5 Apple juice 41 ± 2
Spaghetti, white 49 ± 2 Orange juice 50 ± 2
Spaghetti, whole meal 48 ± 5
Rice noodlesy 53 ± 7
* Low glycemic index varieties were also identified. y Average of all available data.
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S17serum TG.144 South Asians have been shown to have a higher
proportion of total fatty acids as n-6 PUFA and a lower pro-
portion of long-chain n-3 PUFA in plasma and cellular mem-
brane phospholipids as compared to white Caucasians.145 It
has been suggested that an imbalance in dietary n-6 and n-3
PUFA may be important for the development of insulin
resistance and dyslipidemia in South Asians.146
Recommendations
1. Fats should provide not more than 30% of total energy/day
and SFAs should provide nomore than 10% of total energy/
day. For individuals having LDL-C of 100 mg/dl, SFAs
should be <7% of total energy/day.
2. Essential PUFAs [(linoleic acid (LA)] should provide 5e8% of
total energy/day.
3. a-linolenic acid (ALA) should be 1e2% of total energy/day.
4. Optimal ratio of LA/ALA should be 5e10.
5. Long chain n-3 PUFAs should be obtained from fish/wal-
nuts/flaxseeds/canola oil etc.
6. Cis MUFAs should provide 10e15% of total energy/day.
7. TFAs should be <1% of total energy/day.
8. Cholesterol intake should be limited to 200e300 mg/day.
The lower limit of fat should be adequate for the energy
needs (15% of total energy), should prevent essential fatty acid
deficiency (LA, 3%of total energy; ALA, 0.5%of total energy), and
should facilitate optimal absorption of fat-soluble vitamins.39
4.2.1.3.1. Food-based guidelines to ensure optimal fat
quality in Asian Indian diets
1. The recommendation for oils are as follows147:
a. Complete dependence on just one vegetable oil does not
ensure optimal intake of various fatty acids. Combina-
tion/blend of 2 or more vegetable oils (1:1) is recom-
mended. Some recommended oil combinations are- Groundnut/sesame/rice bran/cottonseed þ Mustard/
Canola/Soyabean
 Safflower/sunflower þmustard/olive/Groundnut/Rice
bran
Improvement of n-3 PUFA nutritional status in In-
dian adults has been shown with two of these oil
combinations (groundnut oil/sunflower oil and
canola).147
b. Consumption of butter and ghee (clarified butter) should
be kept to minimum.
c. To limit the intake of trans fats, strictly avoid the use of
partially hydrogenated vegetable fat (vanaspati/marga-
rine) for cooking/frying/baking
d. Coconut oil, palm kernel oil, palm oil and palmolein or
their solid fractions should be substituted for partially-
hydrogenated vegetable oils in foods that require solid
fats (bakery fats, shortening etc). These oils are high in
saturated fats but are trans-fat free.
2. To ensure correct balance of fatty acids from dietary
components other than visible fat, the following dietary
guidelines are recommended146,147:a. Regular consumption of foods with high ALA content
(wheat, pearl millet, pulses, green leafy vegetables,
fenugreek, flaxseed, mustard seeds).
b. Partial substitution of visible fat and invisible fats from
animal foods with whole nuts such as pistachios and
almonds.
c. Moderation in the use of animal foods containing high
fat, saturated fats and cholesterol. For non-vegetarians,
consumption of 100e200 g fish (4e6 pieces)/week is
recommended.
d. Minimizing consumption of premixed, ready-to-eat,
fast foods, bakery foods and processed foods prepared
in partially-hydrogenated vegetable oilssuch as savories
(namkeen).
e. Choose low fat dairy foods such as double toned milk
(fats < 1.5%) or curd prepared from such milk. The
preference of low fat dairy foods would also reduce
ruminant TFAs.
While low-fat diets are generally recommended, it is
important to recognize that decreases in dietary fat intake
may lead to increased carbohydrate consumption and
subsequent weight gain.141,143,148 Patients at risk for the
insulin resistance syndrome are advised to avoid excessive
carbohydrate intake and to consume diets that include
relatively more unsaturated fats.67,149 A diet high in carbo-
hydrates (>60% of total energy) will increase TG, while a
diet that replaces saturated fatty acids with MUFA will
not.67
4.2.1.4. Proteins
1. Protein intake should be based on bodyweight. This should
be 1 g/kg/day, considering the quality of protein in a usual
Indian vegetarian diet.
2. In conjunction with energy intake, the protein intake
should provide 10e15% of the total calories/day in seden-
tary to moderately active individuals.
3. Recommended protein sources:
a. Non-vegetarian: Egg white, fish, and lean chicken.
b. Vegetarian: Soya, pulses, whole grams (channa, rajma,
green gram etc.), milk and low fat dairy products.4.2.1.5. Salt
1. Salt intake should be less than 5 g of sodium chloride (or
about 2 g sodium)/day.
2. Addition of extra salt at the dining table should be avoided.
3. Dietary intake of sodium from all sources (pickles, chut-
neys, namkeens, papads bakery items, potato chips,
popcorn, salty biscuits, preserved meat products, other
pre-prepared and preserved foods, soups, cheese, fast
foods) should be limited. Avoid processed foods that have
high salt content.
4. Reading of food labels to determine sodium content of
the commercial foods should be encouraged. Sodium, in
such foods may be added in the form of sodium benzoate,
monosodium glutamate, baking powder, and baking
soda.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S184.2.1.6. Sugar and artificial sweeteners
1. Free sugars should be less than 10% of total calories/day,
which includes all added sugars and sugars present in
honey, syrups and fruit juices
2. Alternatives to sweetened beverages can be water, skim-
med buttermilk, tender coconut water, low fat milk.
3. Indian sweets, halwa (a gelatinous sweet dish made from
grain flour, ghee, sugar and nuts), kheer (a sweet dish made
from boiling rice withmilk, sugar, cardamoms, saffron and
nuts), puddings, ice creams, sweetened biscuits, cakes,
pastries and baked goods are high in added sugars and
should be restricted.
4. Encourage reading of food labels to determine sugar con-
tent. Some of the names in the ingredients list for the
presence of added sugars include: brown sugar, corn syrup,
dextrose, honey, malt syrup, sugar, molasses and sucrose.
5. Artificial sweeteners could be used in moderation. How-
ever, these do not contain any beneficial nutrients and
longeterm health benefit, if any, is not clear in non-
diabetic individuals. The Food and Drug Administration
(FDA) has approved 5 artificial sweeteners; saccharin
(Sweet ‘N’ Low, Sweet Twin, Necta Sweet), aspartame
(Equal, Sweetex, Sugar free, Sugar free gold), acesulfame-K,
neotame (both are used in beverages, dairy products,
pharmaceutical products, chewing gum etc.), and sucra-
lose (Splenda, Zero, Sugar free natura) as safe. Although
doubts have been raised regarding safety of saccharin, FDA
has approved it to be used in limited quantity due to low
price, good shelf life and heat stability. Stevia (Stevi0cal,
Gwiser) and some sugar alcohols (Sorbitol, xylitol,
mannitol, maltitol etc.) have been approved by FDA under
GRAS (Generally Recognized as Safe) status.
4.2.1.7. Lipid lowering foods. There is also a need to iden-
tify and include foods which have been reported to have lipid
lowering properties. Following are some of the food items that
have been documented to have lipid lowering effect:
1. Oats150,151
2. Nuts152e155
3. Psyllium husk156
4. Cinnamon157,158
5. Flaxseeds159,160
6. Fenugreek161,162
7. Soy163,164
8. Amla165
9. Garlic166
10. Finger Millet167
11. Terminalia arjuna168
Long term studies are required to evaluate the effect of
these food items and appropriate dosage for Asian Indians.
4.2.2. Non-dietary measures
4.2.2.1. Physical exercise (PE). There is ample evidence that
physical inactivity is an important risk factor for development
of CAD, hypertension, obesity, dyslipidemia, type II diabetes
mellitus.3,169,170 Conversely, PE is associated with reduction inrisk for CAD, T2DM, hypertension and obesity.
171 The benefit
of PE on CV risk has been postulated to be multifactorial and
includes beneficial effects on thrombosis, endothelial func-
tion, inflammation, autonomic nervous system, blood pres-
sure, obesity, glucose metabolism, insulin resistance and
lipids.
PE has been documented to raise HDL-C but there is a wide
variability in the HDL-C raising effect of PE, probably due to
differences in baseline characteristics and genetic factors. In
addition, PE has been shown to reduce TG as well as improve
the LDL-C particle size. Thus, in effect, PE directly improves
“atherogenic dyslipidemia”, which is frequently present
among Indians. Therefore, PE may prove to be particularly
helpful in reducing CVD in Indians.
4.2.2.1.1. Effects of PE on HDL-C. Several cross sectional
and prospective cohort studies have shown that HDL-C values
are higher in physically active people as compared to less
active counterparts.172,173Randomized clinical trials address-
ing the effects of at least 12 weeks aerobic exercise on lipids,
where diet was held constant, have also reported significant
increase in HDL-C levels.174e176 In the Health Risk Factors
Exercise Training and Genetics (HERITAGE) Family Study,177
the largest published interventional study, 675 normolipi-
demic subjects were given 20 weeks of supervised exercise
and their HDL-C concentrations increased by 3.6 ± 11% in both
males and females compared with baseline with significant
individual variability.
The reasons for individual variability in HDL-C response to
PE are not entirely clear. Data are inconsistent regarding
whether greater benefit occurs with low vs normal to high
baseline HDL-C.178e180 However subjects with high baseline
TG and low HDL-C as seen in metabolic syndrome appear to
show a significant increase in HDL-C levels (þ4.9%)suggesting
that effect of HDL-C from PE may be linked to baseline TG
levels.179 Another issue is whether effect of PE on HDL-C levels
depends on the amount or intensity of PE. Kraus et al found
that high amount/high intensity exercise significantly
increased HDL-C by 8.8% (p < 0.02) and HDL particle size and
diameter also increased resulting in more beneficial HDL2
fraction.175 However other studies have not shown a consis-
tent relationship between the intensity of exercise and in-
crease in HDL-C.181,182 The Heritage Family Studysuggested
that genetics might play a key role in response of HDL-C to
exercise.177,183 The possible heritable factors suggested
included Apo E, cholesteryl ester transfer protein (CETP) ge-
notype, and lipoprotein lipase (LPL) genotype.184e186
4.2.2.1.2. Effects of PE on TG. PE has a consistent favorable
effect on serum TG levels especially in patients with disorders
of TG-HDL-C axis. Observational studies have shown an in-
verse association between PE and TG levels.173 However the
results from clinical trials have been mixed depending upon
the subset of patients studied.187 It appears that PE affects TG
more significantly in men as compared to women.173,177 A
subset analysis of 200 men in the Heritage Family Study
showed that 20 weeks of exercise reduced TG by 15%, espe-
cially in subjects with abnormalities of TG-HDL-C axis.179 In
another randomized trial of 111 sedentary overweight adults
with dyslipidemia, TG reduced from 10 to 26% in the PE group
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S19compared with 18% increase in the non exercising control
group.175 A recent meta-analysis in the overweight/obese
children and adolescents shows that PE decreases TG in these
subjects.187
4.2.2.1.3. Effects of PE on LDL-C. LDL-C is the most
important lipid predictor of CV events. Although LDL-C can be
reduced by low fat diet, PE alone has shown no significant ef-
fect on LDL-C as reported in several systemic reviews.173,181,187
One review noted that the subset of studies which showed
reduction of LDL-C by PE also showed significant reduction in
body fat and weight.174 A recent meta-analysis of RCTs on the
effects of aerobic exercise on lipids in adults with type II dia-
betes suggests that aerobic exercise lowers LDL-C level in
adults with Type II DM.188 However additional controlled trials
are needed to confirm these observations. Resistance training
over longer periods may also reduce LDL-C.189 Although the
effects of PE on LDL-C are mixed, PE appears to increase the
average size of LDL-C particles and reduce the number of more
atherogenic, small-dense LDL particles.175 This is of particular
importance to Indians who are known to have increased pro-
portions of small-dense LDL.
4.2.2.1.4. Summary and recommendations regarding phys-
ical exercise. Available evidence suggests that aerobic exercise
can raise HDL-C modestly by 3e10%, lower TG by 15e25% and
increase LDL-C particle size. In addition, resistance training
appears to lower LDL-C levels also.
The following recommendations are made as per WHO's
Global Recommendations on Physical activity for health
(2010)189
 Children and young people aged 5e17 years old should
accumulate atleast 60 min of moderate to vigorous in-
tensity (such as jogging) daily.
 Adults aged 18e64 years should do at least 150 min of
moderate-intensity (such as brisk walking) PE throughout
theweek, or do at least 75min of vigorous-intensity aerobic
exercise throughout the week, or an equivalent combina-
tion of moderate- and vigorous-intensity exercise.
 For Adults aged 65 years and above, recommended level of
PE is similar to adults aged 18e64 years but when adults of
this age group cannot do the recommended amounts of
exercise due to health conditions, they should try to be as
physically active as their abilities and conditions may
allow.
While brisk walking is the simplest form of PE that can be
performed, outdoor sports have an added advantage of being a
source of recreation, in addition to being an excellent form of
PE. In addition, in India, folk dances, such as bhangra from
Punjab, andmartial arts (for example, Kalaripayattu of Kerala)
can serve as acceptable, low cost, indigenous forms of healthy
exercise.190
4.2.2.2. Smoking cessation. Smoking intensity has been asso-
ciated with reduction in HDL-C with small but statistically
significant increase in LDL-C.191e193 Some studies have
described small-dense LDL particles among current smokers
and improvements in lipids after smoking cessation, thoughthese findings are less consistent.194 A recent large random-
ized clinical trial suggested that smoking cessation improved
HDL-C, total HDL-C, and large HDL particles, in spite of in-
crease in weight.195 The effect was more marked in women.
The increase in HDL-Cmaymediate part of reduced CVD after
smoking cessation.
Recommendations. Smokers should quit smoking because it
decreases CV mortality and morbidity and also has beneficial
effects on lipids. Though, separate data on bidi smoking and
chewable tobacco are not available, they should also be
avoided.
4.2.2.3. Alcohol consumption. Moderate alcohol intake has
been shown to reduce the risk of CAD by 40e70% compared to
non drinkers and heavy drinkers in several prospective cohort
studies. A recent meta-analysis by Castelnuovo et al of 34
studies has shown a similar effect.196 Several mechanisms
like antioxidant, antithrombotic, enhanced insulin sensitivity
and increase in HDL-C have been hypothesized for this
benefit. However, binge drinking and heavy drinking increase
CV mortality.197 Heavy drinking has also been shown to be
associated with metabolic syndrome, through elevation of
blood pressure and TG, inmale patients with diabetes.198
Although moderate alcohol intake was found to be pro-
tective against MI in the overall study population in the
INTERHEART study,3 it was shown to be harmful for Indians.14
Similarly a cross sectional study by Roy et al among 4465
alcohol users in India shows that alcohol intake increased the
risk for CAD.199
Recommendations. In spite of the fact that moderate
alcohol intake increases HDL-C and has shown cardio-
protective effects in western populations, it has been found
to be harmful in Indian subjects. Hence, alcohol intake, even
in moderation, should preferably be avoided by Indians. In
addition, as heavy drinking can increase TG and blood pres-
sure and causemetabolic syndrome, apart from causing other
non-lipid harmful effects, it should completely be avoided.
4.2.2.4. Yoga. Yoga is an ancient Indian and holistic tech-
niquewhich has been shown to control stress. It has also been
shown to have several cardio protective effects in several
small studies like control of hypertension,200 body weight,
blood sugar, and improvement in lipids.201e203 Many
controlled studies have demonstrated that yogamay be useful
for regression of early204 and advanced coronary athe-
rosclerosis.205e207 A recent controlled trial of secondary pre-
vention in blacks showed that meditation (which is an
essential component of yoga) reduced major adverse CV
events (death, MI, stroke) by 48% over a 5.4 years average
follow up.208 These studies have also demonstrated a marked
decrease in TC, TG and LDL-C levels with yoga. In addition,
one study in normal volunteers has shown an increase in
HDL-C also, apart from reductions in TC, TG and LDL-C levels.
A recent study suggests that yoga may improve lipid profile in
patients with end stage renal disease.209
Recommendations. Psychosocial stress is an important but
neglected risk factor for CAD. Yoga can control the stress and
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S20has several other cardio-protective effects which could be
useful in primary and secondary prevention of CAD. Several
small studies suggest that yoga can affect lipids favorably.
Therefore, although no large studies are available, in view of
its several cardio-protective effects including possible
improvement in lipids, the present guidelines encourage
practice of yoga among Indians.
4.3. Pharmacological therapy
4.3.1. Statins
Statins are currently the most effective drugs available for
lowering LDL-C. Statins act by inhibition of 3-hydroxy 3-
methylglutaryl coenzyme A (HMG-CoA) reductase, which re-
sults in reduction in cholesterol concentration in the hepa-
tocytes, leading to up-regulation of LDL receptors and
subsequent increased clearance of LDL as well as VLDL
particles.210,211
4.3.1.1. Statin pharmacokinetics and clinical benefits. Statins
can be grouped as natural (those derived from fungal
fermentation) e.g. e lovastatin, pravastatin and simvastatin;
and the more recent synthetic ones fluvastatin, atorvastatin,
cerivastatin, rosuvastatin and the new pitavastatin. Table 9
summarizes the pharmacology of commonly available sta-
tins. Most statins are metabolized by CYP P 450 3A4 enzyme
systems (Lovastatin, simvastatin, atorvastatin) whereas some
synthetic statins like fluvastatin and rosuvastatin are metab-
olized by CYP P450 2C9 pathway. Pitavastatin has minimal
effects on CYP P450, while pravastatin has none. Since a large
number of drugs are metabolized by CYP P 450 3A4 pathway,
caution needs to be exercised while choosing a statin in-
patients already on multiple other drugs. Statins metabolized
by alternate pathways are to be chosen if there is evidence of
hepatic or muscle toxicity by a statin with CYP P 450 3A4
pathway.
4.3.1.2. Dosages. Statins as a class reduce LDL-C levels; the
dose/response relationship is log linear, which means that
although the initial dose lowers LDL-C from 25% to 45%,
additional doublings of the statin dose result in only an
additional 6%e7% of LDL-C lowering. The standard dosages as
well asmaximal dosages of various statins are shown in Table
8. Although the most recent ACC/AHA guidelines on choles-
terol management have recommended moderate- or high-
intensity statin therapy regardless of baseline LDL-C,133 the
present document recommends initiating therapy at the
commonly tolerated doses of statins. The rationale for thisTable 8 e Effective clinical doses of different statins.
Statin Daily dose (mg) to lower
LDL-C by around 30%
Maximal
dose (mg)
Lovastatin 40 80
Pravastatin 40 80
Simvastatin 20 40
Fluvastatin XL 80 80
Atorvastatin 10 80
Rosuvastatin 5 40
Pitavastatin 2 4 T
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S21recommendation is discussed in Section 5. This of course does
not apply to patients presenting with an acute CV event, in
whom intensive statin therapy is recommended from the
outset (ref. Section 6.3).
In general, the reduction in LDL-C increases with statin
dose and for most statins equivalent doses can achieve the
targeted levels of LDL-C. Fluvastatin XR 80 mg, lovastatin
40 mg, pravastatin 40 mg, simvastatin 20 mg, atorvastatin
20 mg, rosuvastatin 10 mg and pitavastatin 2 mg are equiva-
lent in decreasing LDL-C by 30e40%. Greater than 40%
reduction is expected with atorvastatin >40 mg, rosuvastatin
20 mg, and pitavastatin 4 mg.
Lower dosages of statin are recommended in patients
above 75 years or age and in those requiring co-administration
of drugs that inhibit the CYP3A4 or 2C9 pathways such as
cyclosporine. In addition, it is advisable to avoid consumption
of large quantities of grape juice while taking statins that are
metabolized by CYP3A4 pathway (i.e., avoid >960 ml daily
while taking simvastatin or lovastatin or >1.2 L while taking
atorvastatin).
4.3.1.3. Adverse effects. Statins are safe drugs. In large clinical
trials, side effects of statins have been quite rare. Liver related
toxicity is estimated to happen in 1e2% cases while actual
muscle injury being much rarer at 0.1e0.2%.
4.3.1.3.1. Muscle toxicity. Statins may cause different
types of muscle toxicity which can be classified as follows-
 Myalgia e characterized by muscle ache without creatine
phosphokinase (CPK) elevation. Reported in up to 10% of
the patients.
 Myositis-diagnosed when muscle pain and tenderness are
associated with elevation of CPK 3 to 10 times upper limit
of normal (ULN), incidence 0.1%, or
 Rhabdomyolysis-severe muscle pain in conjunction with
increases in CPK >10000 or >10 times the ULN, associated
with myoglobinuria or elevated serum creatinine.
Routine measurement of CPK is not required prior to initi-
ating statin therapy. However, in patients at high risk ofmuscle
toxicity, such as elderly patients, patients on concomitant drug
therapy likely to increase the risk of myotoxicity or those with
hypothyroidism, reduced renal or hepatic function, rheuma-
tologic disorders such as polymyalgia rheumatica, steroid
myopathy, vitamin D deficiency, or primarymuscle diseases, it
is advisable to obtain CPK levels at baseline.
If mild to moderate muscle symptoms develop during
statin therapy, discontinue the statin until the symptoms can
be evaluated. If muscle symptoms resolve, and if no contra-
indication exists, the original or a lower dose of the same
statin should be restarted establish a causal relationship be-
tween the muscle symptoms and the statin therapy. If a
causal relationship exists, the original statin should be dis-
continued and a low dose of a different statin should be
started once muscle symptoms have resolved. If this is toler-
ated, then gradually the dose should be increased as per the
patient's tolerance.
However, if the muscle symptoms or elevated CK levels do
not resolve completely even after 2 months of cessation ofstatin therapy, other causes of muscle symptoms should be
looked for. If persistent muscle symptoms are determined to
arise from a condition unrelated to statin therapy, or if the
predisposing condition has been treated, statin therapy can be
resumed at the original dose.
In patients who develop unexplained severe muscle
symptoms or fatigue develop during statin therapy, statin
therapy should be promptly discontinued and the possibility
of rhabdomyolysis addressed by evaluating CPK, creatinine,
and a urinalysis for myoglobinuria. If rhabdomyolysis is
confirmed, then restarting statin therapy in such patientsmay
not be advisable unless a temporary, reversible cause of
rhabdomyolysis (such as severe acute infection, major sur-
gery, trauma, severe metabolic, endocrine and electrolyte
disorders and uncontrolled seizures, unaccustomed exercise,
etc.) could be found.
4.3.1.3.2. Liver function abnormality. Statins have been
associated with biochemical abnormalities of liver function
with alanine aminotransferase (ALT) elevation in <1e2%,
although increasing to 2e3% with higher doses. Liver enzyme
changes generally occur in the first 3 months of therapy
related to changes in the lipid components of the hepatocyte
membrane, leading to an increase in permeability. Serious
liver injury with statins is rare.
ALT and aspirate aminotransferase (AST) should be
checked prior to the initiation of therapy and when clinically
indicated. Statin therapy should be avoided in patients with
ALT >3 times ULN at baseline, until a treatable cause can be
found and the liver function abnormality has been corrected.
Routine periodic monitoring of liver enzymes does not appear
to be effective in detecting or preventing serious liver injury
and is therefore not required.
If symptoms suggesting hepatotoxicity (e.g., unusual fa-
tigue or weakness, loss of appetite, abdominal pain, dark-
colored urine or yellowing of the skin or sclera) arise during
statin therapy, then liver function tests should be repeated
and statin therapy should be temporarily discontinued. These
patients should be monitored until the abnormalities resolve.
Nearly 70% of cases resolve spontaneously. Once abnormal-
ities resolve, statin can be restarted cautiously, using a
smaller dose and possibly a different statin than the previ-
ously used one. If liver injury recurs and an alternate etiology
is not found, statin therapy may have to be permanently
discontinued.
Statins should be used with caution in patients who
consume substantial quantities of alcohol and/or have a his-
tory of liver disease.
4.3.1.3.3. Other important adverse effects. Statin therapy is
associated with verymodest excess risk of new onset diabetes
(1 excess case per 1000 individuals treated 1 year with
moderate-intensity statin therapy and 3 excess cases per 1000
individuals treated for 1 year with high-intensity statin ther-
apy). However, the benefit with statin therapy clearly out-
weighs this small risk of new-onset diabetes.133
There have also been concerns of increased risk of cancers,
hemorrhagic stroke and cognitive impairment with statin
therapy but no causeeeffect relationship has been estab-
lished, in any of the trials.133
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S224.3.1.4. Clinical evidence. The benefits of statins have been
proven in multiple clinical trials and are extremely robust.
They have been tried, tested and proven in almost every
category of dyslipidemia and CVD, ranging from primary pre-
vention to established CVD including post ACS, post-coronary
revascularization (percutaneous or surgical) patients also.
From mild elevation of LDL-C to combined dyslipidemia, the
benefits are durable. Tables 10 and 11 summarize the evidence
showing beneficial effects of statins in large clinical trials in
primary and secondary prevention settings, respectively.
4.3.2. Fibrates
Fibrates reduce TG levels by 20e50%, and increase HDL-C by
10e20%.67 They also reduce small, dense LDL particles by
promoting a shift to larger, more buoyant particles which
have higher binding affinity for the LDL receptor.217,218
Fibrates are considered first-line therapy for severe hyper-
triglyceridemia while as an adjunct to statins, they are a
therapeutic option for combined dyslipidemia.
4.3.2.1. Pharmacology. Fibrates act through the peroxisome
proliferator receptor-a (PPAR-a) agonism,218 which perhaps is
responsible for their multiple beneficial non-lipid pleiotropic
effects on endothelial function, vascular inflammation, and
fibrinolytic pathway.
Available fibrates are: fenofibric acid derivatives, gemfi-
brozil and bezafibrate.
4.3.2.1.1. Gemfibrozil. After oral administration, Gemfi-
brozil reaches peak plasma concentration at around 1e2 h.
The absorption of the drug is best when given before meals.
Approximately 70% of an administered dose is excreted in the
urine, mostly as the glucuronide conjugate. Gemfibrozil is
highly bound to plasma proteins and there is a potential for
displacement interactions with other drugs. The elimination
half-life is approximately 1.1 h.218
4.3.2.1.2. Fenofibrate. Fenofibrate is the most commonly
used fibrate in clinical practice. After absorption in to the
circulation, it is hydrolyzed to fenofibric acid, which is the
active metabolite. Approximately 99% of it is protein bound.
Fenofibricacid is metabolized by conjugation with glucuronic
acid and excreted primarily in the urine (60%) and to a lesser
extent (~25%) in the feces. The elimination half-life is
approximately 20 h.218 Neither fenofibrate nor fenofibric acid
undergo metabolism by CYP P450.
A major problem with fenofibrate is its poor water solubi-
lity resulting in low and unpredictable oral bioavailability.
Micronized and nano-particle formulations have been devel-
oped to overcome these challenges but oral bioavailability
related issues still remain. More recently, choline salt of
fenofibric acid has been developed which does not have most
of these problems. It has good (~81%) and predictable
bioavailability and can be taken regardless of meals. It is the
only preparation of fenofibric acid recommended for use at
present.
4.3.2.1.3. Bezafibrate. Bezafibrate has an elimination half-
life of 1e2 h and protein binding of 94e96%. Excretion is
almost exclusively renal with 95% recovered in the urine.
Table 11 e Cardiovascular benefits of statins in secondary prevention clinical trials.
Study Population Statin; duration
of follow-up
LDL-C reduction Efficacy against CHD Efficacy against
stroke
HPS282 Age 40e80 y with coronary disease, other occlusive
disease, diabetes
Simvastatin 40 mg/day
vs. placebo; 5 years
37% Significant reduction in total
mortality,fatal and nonfatal MI,
revascularization
Yes
PROSPER336 Age 70e82 y with history of, or risk factors for,
vascular disease
Pravastatin 40 mg/day
vs. placebo; 3.2years
3% No reduction in total mortality, but
significant reduction in fatal and nonfatal
CHD
No, although a
decrease in TIA
(low rate of stroke
in placebo group)
CARE279 4159 subjects post MI; mean age, 59 y Pravastatin 40 mg/day
vs. placebo; 5years
28% Significant reduction of primary endpoint Yes
LIPID280 9014 subjects aged 31e75 with MI and ACS Pravastatin 40 mg/day
vs. placebo; 5years
25% Significant reduction of primary endpoint Yes
TNT337 10,001 subjects age 35e75 y with stable CHD Atorvastatin 10 mg/day
vs. 80 mg/day; 4.9years
77 mg/dl with 80 mg
dose and 100 mg/dl
with 10 mg dose
No difference in total mortality but
significant reduction in primary combined
endpoint, fatal and nonfatal MI and major
coronary events
Yes
IDEAL338 8288 subjects <80 y with prior MI; 4.8 years Simvastatin 20 mg/day vs.
atorvastatin 80 mg/day; 4. years
22% lower values
achieved with
atorvastatin
(79 vs. 102 mg/dl)
No significant lowering of primary
combined endpoint; no significant
decrease in any coronary event
No
ACS-Acute Coronary Syndrome, CARE-Cholesterol And Recurrent Events; CHD-coronary heart disease; HPS-Heart Protection Study; IDEAL-Incremental Decrease in Clinical Endpoints Though
Aggressive Lipid Lowering, LDL-C-low density lipoprotein cholesterol, LIPID-Long Term Intervention in Ischemic Patients, MI- myocardial infarction, PROSPER-Prospective Study of Pravastatin in The
Elderly at Risk, TIA-transient ischemic attack, TNT-Treat To New Targets.
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S244.3.2.2. Indications. Fibrates are indicated as first-line therapy
(along with intensive life-style measures) for severe hyper-
triglyceridemia (TG > 500 mg/dl) or as an adjunctive therapy
with statins when there is persistent elevation of serum TG
levels despite optimum life-style measures and statin ther-
apy. Choline salt of fenofibric acid is the only fibrate approved
by the USFDA for use with a statin.
4.3.2.3. Dosage
4.3.2.3.1. Fenofibrate. The recommended initial dose of
fenofibric acid is 135 mg once a day, with lower doses (45 mg/
d) recommended for those with impaired renal function
[glomerular filtration rate (GFR) < 60 mL/min/1.73 m2].
4.3.2.3.2. Gemfibrozil. The recommended dose of gemfi-
brozil is 600 mg twice a day, given 30 min before the meals.
The dose needs to be reduced to 600 mg once a day when GFR
is < 60 mL/min/1.73 m2.
4.3.2.3.3. Bezafibrate. The recommended dosage of beza-
fibrate is 200 mg twice or thrice a day (or 400 mg modified
release formulation once daily). Dose adjustment according to
renal function is indicated.
4.3.2.4. Contraindications. Fibrates are pregnancy category C
drugs and should be used during pregnancy only if the benefit
justifies the potential risk for the fetus. Fibrates are contra-
indicated in nursing mothers. In addition, extreme caution
needs to be exercised when prescribing fibrates to those with
end-stage renal disease.
4.3.2.5. Adverse effects. Fibrate use can cause myotoxicity
including myopathy and rhabdomyolysis especially when co-
administered with a statin, particularly in patients with dia-
betes mellitus, renal failure, hypothyroidism and in elderly
patients.219
The risk of myotoxicity increases by a factor of 33 when
gemfibrozil is combined with a statin as opposed to fenofi-
brate. If gemfibrozil needs to be combined with a statin, flu-
vastatin may be preferred, since there is no significant effect
of gemfibrozil on its concentration.219,220
Fenofibratestatin combination was evaluated in around
1000 patients (of the total population of 9795 patients) who
received both the drugs, in the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) trial. There were no re-
ported cases of rhabdomyolysis.221 Similar data emerged out
of the Action to Control Cardiovascular risk in Diabetes
(ACCORD) trial.134 However, fenofibrate can increase serum
creatinine levels by 10e20% which return to normal on
discontinuation of therapy. In the ACCORD trial, the study
drug was discontinued by 2.4% patients in the fenofibrate
group and by 1.1% in the placebo group because of a decrease
in the estimated GFR. It is therefore recommended that serum
creatinine should be checked before initiating fibrate therapy,
and routine creatinine monitoring is required in patients with
preexisting chronic kidney disease.220
In a pooled analysis of 10 placebo-controlled trials, rise of
hepatic enzymes to > 3times the ULN occurred in 5.3% of pa-
tients taking fenofibrate compared to 1.1% on placebo. Hence,liver enzymes should be periodically monitored during ther-
apy and therapy to be discontinued if enzyme levels persist >3
times the ULN.
The dosage of coumarin anticoagulants may need to be
adjusted during fibrate therapy to prevent bleeding
complications.220
4.3.2.6. Clinical evidence. A number of trials have evaluated
fibrates, either alone or in combination with statin therapy. In
the FIELD trial, 9795 diabeticswhowere not on any statin were
randomized to receive fenofibrate or a placebo. After an
average follow-up of 5 years, no significant difference was
seen between the two groups in the composite endpoint of
CHD death and nonfatal MI. However, fenofibrate therapy
resulted in significantly lower risk of non-fatal MI and coro-
nary revascularization.221 Similarly, in the ACCORD trial, in
which fenofibrate was added on top of open label simvastatin,
no overall benefit was seen with fenofibratein reducing the
combined primary endpoint of first nonfatal MI, non fatal
stroke and CHD death or individual components, despite
reduction of triglycerides and increase in HDL-C.134
However, a subgroup analysis involving patients with TG
more than 204mg/dl and HDL-C <34mg/dl showed significant
benefit with fenofibrate therapy in both the above trials. There
were around 2014 patients in the FIELD trial who showed a CV
event reduction of 27% while in the 941 patients of ACCORD
trial there was a CV endpoint reduction of 31%.222,223 These
results were confirmed in a meta-analysis that included 5
large trials with fibrates.135
4.3.3. Bile acid sequestrants (BAS)
Cholestyramine, colestipol and colesevelam are the three
commonly available BASs. Cholestyramine and colestipol
were initially available as water insoluble powder, but coles-
tipol was subsequently developed as a tablet form to improve
palatability and compliance.224 Colesevelam has a unique
polymer structure accounting for its higher capacity bile acid
binding (Table 12).
4.3.3.1. Mechanism of action. Bile acids are secreted in the bile
from the liver and gallbladder into the intestine. They emul-
sify the fat in food, facilitating absorption. A major portion of
the secreted bile acid is reabsorbed from the intestines and
returned to the liver via the portal circulation, thus, forming
the enterohepatic cycle. However, about 5% escape absorption
and additional bile acids are synthesized from cholesterol by
the liver. BASs bind with the negatively charged bile acids and
bite salts in the small intestine promoting their excretion. This
results in increased conversion of hepatic cholesterol in to bile
acid and a compensatory increase in LDL-Cuptake. Mono-
therapy with BAS lowers LDL-C by 5e30% in a dose dependent
manner.225
4.3.3.2. Pharmacology. BASs are not absorbed or metabolized,
and there is no interference with systemic drug metabolizing
enzymes.225
4.3.3.3. Indication. BASs are indicated to reduce elevated LDL-
C as monotherapy (when statins are contraindicated) or in
Table 12 e Currently available bile acid sequestrants for clinical use.
Bile acid
sequestrant
Initial dosage Maintenance dosage LDL-C reduction Comments
Cholestyramine
resin
8 g/day in
divided doses
16e24 g/day as monotherapy;
lower doses if used with statins
Varies from 8.7% to 28%
depending on dosage of resin
Take other drugs 1 h before or
3 h after, psylium augments
action
Colestipol resin 10 g/day in
divided doses
16e24 g/day as monotherapy;
lower doses if used with statins
Similar to cholestyramine,
varies with dosage of resin
Take other drugs 1 h before or
3 h after, psylium augments
action
Colesevelam Two or three
625 mg tabs twice
daily (7 tabs/day max)
19% (with 3.8 g/day dose) Take with a large glass of
water, lowers HbA1C in type
2 diabetes
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S25combination with a statin. Colesevelam is approved for use as
adjunct to diet and exercise.
4.3.3.4. Dosage
4.3.3.4.1. Cholestyramine. The recommended starting
dose is 4 g once or twice a day followed by maintenance daily
dose is 8e16 g, divided into 2 doses. Dose increments should
be gradual with periodic assessment of lipid levels at intervals
of 4 weeks. The maximum recommended daily dose is 24 g.
4.3.3.4.2. Cholestipol. The recommended dose is 5e30 g/
day of granules or 2e16 g/day of tablets given once or in
divided doses. The starting doses should be 5 g granules once a
day, or two 1 g tablets once or twice a day and should be
gradually increased every 1e2 months.
4.3.3.4.3. Colesevelam. Colesevelam can be used at lower
doses since it has greatest bile acid binding capacity among
BAS. The recommended dose is six 625 mg tablets once a day
or divided in two doseswithmeals. It can be dosed at the same
time as a statin or the two drugs can be dosed apart. After
initiation, lipids should be checked in 4e6 weeks. The decline
in LDL-C is usually evident within 2 weeks with colesevelam.
4.3.3.5. Contraindications. As BASs increase serum TG levels,
their use is contraindicated in patients with baseline
TG > 300 mg/dl or those who have type III
hyperlipoproteinemia.
Cholestyramine and colestipol are pregnancy category C
drugs. Their use during pregnancy or lactation, or by women
of childbearing age requires that potential benefit be weighed
against hazard to fetus.
Colesevelam is a pregnancy category B drug and should be
used during pregnancy only if clearly needed. It is not ex-
pected to be excreted in human milk because it is not absor-
bed systemically from the GI tract.
4.3.3.6. Adverse effects. BAS may produce gastro-intestinal
(GI) side effects like constipation, dyspepsia and flatu-
lence. To minimize GI slide effects with BAS, low initial
doses are to be started. For constipation, increased fluid and
dietary fiber intake are recommended and stool softeners
may be added as needed. Less frequent adverse effects
include abdominal discomfort and/or pain, flatulence,
nausea and vomiting. BASs are not recommended in pa-
tients with gastroparesis, other gastro-intestinal motilitydisorders, those who have had major gastrointestinal
motility tract surgery, patients who may be at risk of bowel
obstruction and those with complete biliary tract obstruc-
tion. Because of the tablet size, colesevelam and colestipol
should be used with caution in patients with dysphagia or
swallowing disorders, since they may cause dysphagia or
esophageal obstruction.
BASs can increase triglycerides. For example, colesevelam
may increase triglycerides by 5% in patients with primary
hyperlipidemia whereas median increases in triglycerides of
18e22% have been reported in clinical studies treating pa-
tients with type 2 diabetes mellitus. Chronic use of BAS may
be associated with increased bleeding tendency due to hypo-
prothrombinemia and vitamin K deficiency.
BAS may decrease absorption of fat-soluble vitamins.
Patients on vitamin therapy should take vitamins at least 4 h
before the BAS. If a patient is taking other medications in
addition to cholestyramine or colestipol, the other medica-
tions should be taken 1 h before or 4 h after the BAS. Cole-
sevelam is a more specific BAS, but may reduce GI absorption
of some drugs. Drugswith a known interaction that should be
taken at least 4 h prior to a colesevelam dose are: cyclo-
sporine, glyburide, levothyroxine, oral contraceptives and
phenytoin.
4.3.3.7. Clinical evidence (Table 13). The most significant
outcome trial was the Lipid Research Clinics Coronary Primary
Prevention Trial (LRC-CPPT), which demonstrated a 19%
decrease in the risk of combined CHDdeath and nonfatalMI in
men with elevated cholesterol treated with 24 g/day of
cholestyramine.226
In combination trials, the addition of colesevelam to a
statin resulted in an additional 10e16% reduction in LDL-C.
However, the effect of colesevelam on CV morbidity and
mortality has not been determined.
4.3.3.8. When to use. If treatment with a statin does not
achieve the LDL-C goal selected for a patient, intensification of
LDL-C lowering drug therapy with a BAS is reasonable. In
addition, BAS provides an alternative to statins as initial drug
therapy for LDL-C lowering. The combination of BAS and
ezetimibe can have additive effects on LDL-C lowering, and is
useful for patients who do not tolerate a statin or for whom
statins are contraindicated.225
An advantage of the statin-BAS combination is that here
may be a reduction in blood glucose in diabetic patients.
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Niacin reduces LDL-C, VLDL-C, TG, Lp(a) and increases HDL-
C.232,233Its primary effect is to down-regulate lipolysis and
production of free fatty acids. This leads to a reduction in the
amount of free fatty acids released from the adipocyte that are
available to the liver for TG and VLDL production. Decreased
levels of VLDL lead to diminished hepatic and peripheral
production of IDL and LDL. At the same time, niacin increases
apo-A1 by decreasing its cellular uptake resulting in HDL-C
increase.232,234,235
Although niacin is amongst the most effective agents to
raise HDL-C, results of recent large trials have shown no
benefit, and even harm, with addition of niacin to statin
therapyalone.236,237In addition, niacin has several side effects.
As a result, niacin is currently not recommended for treat-
ment of any form of dyslipidemia.
4.3.5. Omega-3-fatty acids
The omega-3 fatty acids (OFA) include the marine-derived
long-chain fatty acids eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA). They lower triglycerides in patients
with severe hypertriglyceridemia. OFA is available as an 1 gm
liquid-filled gel capsule containing at least 900mg ethyl esters
of OFA derived from fish oils (465 mg EPA and 375 mg DHA).
4.3.5.1. Mechanism of action. OFA interfere with many tran-
scription factors and lower triglycerides.
4.3.5.2. Pharmacology. OFA is manufactured by trans-
esterification of fish oil. After intestinal absorption and
breakdown of the ethyl esters, the resulting EPA and DHA
enter the circulation.
4.3.5.3. Indications. For patients with mixed hyperlipidemia
who attain LDL goal with statins, OFA supplementation is a
reasonable therapeutic option as an alternative to fibrate to
achieve non-HDL target goals.
Forpatientswithveryhigh triglyceride levels>500mg/dl, the
initial therapeutic goal is to lower triglyceride levels to prevent
pancreatitis, and OFAs are indicated as an adjunct to diet.
4.3.5.4. Dosage. Daily dose of OFA of 4 g/day is recommended
for severe hypertriglyceridemia. The daily dose may be taken
as a single 4 g dose or as two 2 g doses. The capsule should be
swallowed whole and not broken open or chewed. Lower
doses (1e2 gm/d) may be sufficient for less severe
hypertriglyceridemia.
4.3.5.5. Contraindications. People with sea fish allergy should
be careful with OFA.
Prescription OFAs are pregnancy category C drugs and
should be used during pregnancy only if the potential benefit
to the patient justifies the potential risk to the fetus. It is not
known whether OFAs are excreted in human milk, and
therefore caution should be exercised when administering
OFAs to a nursing woman.
4.3.5.6. Adverse effects. Dyspepsia, and/or taste perversion
have been reported in 3e4% of patients in clinical studies.
Some studies have demonstrated a prolongation of bleeding
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S27time, but the times reported have not exceeded normal limits
and did not produce clinically significant bleeding episodes.
4.3.5.7. Clinical evidence. In patients with severe hyper-
triglyceridemia (levels > 500 mg/dl), 4 g prescription of OFA
decreased triglycerides by 45%and increased HDL by 9>%. In
patients treated with simvastatin 40 mg/day and having
persistently elevated triglycerides in the range of 200e499mg/
dl, the addition of 4 g prescription OFA resulted in reductions
in triglyceride levels by 23% and increases in HDL of 4.6%and
LDL of 3.5%.
Japan EPA Lipid Intervention Study (JELIS), compared a low
dose statin plus either EPA (1.8 g) or placebo. Subgroup anal-
ysis of primary prevention patients with baseline triglyceride
levels>150 mg/dl and HDL <40 mg/dL demonstrated that the
combination therapy reduced CVD risk by 53% compared with
statin monotherapy.238 The effect of prescription OFA on CV
mortality andmorbidity in patientswith elevated triglycerides
has not been determined.
4.3.6. Ezetimibe
Ezetimibebelongs to a class of lipid-lowering compounds that
selectively inhibit absorption of cholesterol by the small
intestine.225
Ezetimibe reduces LDL-C and triglycerides and increases
HDL-C in patients with combined hyperlipidemia. The
maximal response is generally achieved within 2 weeks and
maintained during chronic therapy. The addition of ezetimibe
to either a statin or fenofibrate is more effective in lipid
lowering than with either agent alone. However, the effect of
ezetimibe as monotherapy or in addition to a statin or feno-
fibrate on CVmorbidity and mortality has not been proven.239
4.3.6.1. Mechanism of action. Ezetimibe acts by interfering
with a sterol transporter, which prevents transport ofmicelles
into intestinal cells. The reduction in delivery of cholesterol to
the liver causes a drop of hepatic cholesterol stores and a
compensatory increase in LDL receptors and therefore
increased clearance of cholesterol from the blood.240
4.3.6.2. Pharmacology. Ezetimibe is metabolized in the small
intestine and liver via glucuronide conjugation with subse-
quent biliary and renal excretion. Both ezetimibe and its
glucuronide metabolite have an elimination half-life of 22 h.
Excretion of the drug is 78% in feces and 11% in urine. Ezeti-
mibe is highly (>90%) bound to plasma proteins. It is neither
an inhibitor nor an inducer of the CYP P450 isoenzymes.
4.3.6.3. Dosage. The recommended dose of ezetimibe is 10mg
once a day. Concomitant food administration has no effect on
absorption, and ezetimibe can be administered with or
without food. No dosage adjustment is necessary in patients
with mild hepatic or renal impairment.
4.3.6.4. Contraindications. Ezetimibe is a pregnancy category
C drugs. There are no adequate, well e controlled studies of
ezetimibe in pregnant women.
4.3.6.5. Adverse effects. Ezetimibe monotherapy does not
cause significant elevations of hepatic transaminases. Theincidence of increased transaminases is marginally higher in
patients receiving ezetimibe in combination with a statin
(1.3%) compared to patients treated with a statin alone (0.4%).
When used with a statin, liver function tests should be per-
formed at the initiation of therapy and subsequently as rec-
ommended for statins.239
4.3.6.6. Clinical evidence. As monotherapy, ezetimibe pro-
duces LDL-C reductions of 15e25% but there is a compensa-
tory increase in cholesterol synthesis. Combining it with
statins results in greater decrease in LDL-C, as compared to
ezetimibe monotherapy. The advantage of the combination is
the low incidence of side effects, but the disadvantage is the
lack of clinical outcome data for ezetimibe.225
In the Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression (ENHANCE) trial, the
addition of ezetimibe to statin therapy did not significantly
change CIMT compared to statin monotherapy, despite a
>50 mg/dl lowering of LDL in the combination therapy
group.241
4.3.6.7. When to use. If treatment with a maximally tolerated
dose of statin does not achieve the LDL-C goal selected for a
patient (often in those with primary hyperlipidemia), inten-
sification of LDL lowering drug therapy with ezetimibemay be
considered. It is also indicated for use in combination with
statin and fenofibrate for the reduction of elevated LDL-C and
non-HDL-C in patients with mixed hyperlipidemia.5. The 2013 ACC/AHA guidelines on lipid
management and their relevance to the present
document
The ACC and AHA, in collaboration with the National Heart,
Lung and Blood Institute (NHLBI), have recently released
new guidelines for the management of blood cholesterol in
adults.133 These guidelines serve to update the previously
available document for this purpose, the NCEP ATP III rec-
ommendations.67 However, unlike all the currently existing
guidelines on lipid management, including those from the
European Society of Cardiology68 and the American Dia-
betes Association,242 the new document proposes a com-
plete paradigm shift in the approach towards lipid
management and, therefore, has become a subject of
intense controversy. The fundamental reason underlying
this departure from the conventional principles is that the
current document is purposefully based predominantly on
data derived from randomized controlled trials (RCTs),
systematic reviews and meta-analyses of RCTs. The expert
committee identified a few critical questions and addressed
them based on such available data, while choosing to make
no recommendation, except in few circumstances, if a
relevant RCT or meta-analysis was not available to answer
a particular critical question. As a result, the document has
become vastly different and less encompassing than its
previous iterations. Given the far-reaching recommenda-
tions made in the new guidelines, a careful review of the
same is required to determine their relevance to the Indian
populations.
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Following are the key recommendations of the new ACC/AHA
lipid guidelines:
1. The expert panel found no evidence to support the use of
specific LDLeC or non-HDLeC targets for either primary or
secondary prevention of CVD and therefore has not rec-
ommended any specific lipid targets.
2. Four major statin benefit groups were identified for whom
at least moderate to high-intensity statin therapy was
strongly recommended-
a. Those with clinically manifest atherosclerotic CVD,
b. Those with primary elevations of LDLeC >190 mg/dl,
c. Diabetics aged 40e75 years with LDLeC 70e189 mg/dl
and without clinical CVD, or
d. Those without clinically manifest atherosclerotic CVD
or diabetes with LDLeC 70e189 mg/dl and estimated 10-
year CVD risk >7.5%.
While high-intensity therapy is recommended for the first
3 groups, moderate-to high-intensity statin therapy is
considered appropriate for the fourth group.
3. Regular use of non-statin lipid-lowering drugs is discour-
aged, placing major emphasis on using appropriate dose
statin therapy only.
4. The expert panel made no recommendations regarding the
initiation or discontinuation of statins in patients with
functional class IIeIV ischemic systolic heart failure or in
patients on maintenance hemodialysis.
5.2. Relevance to Indian populations
5.2.1. Statin dose
The new guidelines recommend using high-intensity statin
therapy, and if not possible then at least moderate-intensity
therapy, in all the high risk groups identified. High-intensity
statin therapy is defined as the one that results in 50%
reduction in LDL-C from baseline whereasmoderate-intensity
is the one that lowers LDL-C by 30e50%. These recommen-
dations are based on the fact that the large-scale RCTs
showing benefit with statin therapy had used these dosages
only and had resulted in this much reduction in LDL-C.133
It is well known that Asians respond more strongly to
statins as compared to their western counterparts. Among
Asians, atorvastatin 10e20 mg/d and rosuvastatin 5e10 mg/
d have been shown to result in as much as 40e50% reduction
in the LDL-C.243e247 In the IRIS study (Investigation of Rosu-
vastatin In South Asians), the largest statin efficacy trial in an
exclusively South-Asian population, 740 patients in US and
Canada received 6 weeks of treatment with rosuvastatin 10 or
20 mg/d and atorvastatin 10 or 20 mg/d. Nearly 40%, 47% and
45% reduction in LDL-C was seen with atorvastatin 10 mg,
20 mg and rosuvastatin 10 mg/d dose, respectively.247 It is
believed that lower body mass index and slower statin
metabolism are the possible reasons underlying heightened
statin response in Asians.243,248e250
Unfortunately, no large-scale study has yet compared CV
event reduction with regular dose versus high-dose statintherapy exclusively in Asian populations. However, it is
noteworthy that in most of the larges-scale statin trials, the
observed benefit on CV risk reduction was directly propor-
tional to the reduction in LDL-C,251 suggesting that it may be
possibleto achieve a similar degree of CV event reduction with
lower dosages of statins in Asian populations. Indeed, in the
MEGA (Management of Elevated Cholesterol in the Primary
Prevention Group of Adult Japanese) trial enrolling 7832 in-
dividuals, 10e20 mg pravastatin every day resulted in 33%
reduction in CHD events as compared to diet alone.252
Exaggerated statin response in Asians also raises concerns
of increased risk of adverse effects. Although no causal rela-
tionship has been established, some studies have reported
increased risk of hemorrhagic strokes and cancers in Asian
patients achieving very low serum cholesterol levels.253e257 In
contrast, a recent 12-week study in Indian patients presenting
with ACS has demonstrated good safety and tolerability pro-
file of intensive statin therapy.258 However, this study was
small and had only a short follow-up. In addition, apart from
the risk of side effects, high dose statin therapy is also asso-
ciated with increased cost, which is an important consider-
ation in Indian patients with limited financial affordability.
Given these observations, it remains debatable to routinely
recommend high dose statin therapy for Indian patients in
whom the desired LDL-C reduction can be achieved with
much lower dosages. A more prudent approach would be to
start treatment with commonly used dosages and then up-
titrate the dose if the desired magnitude of LDL-C reduction
is not achieved.
5.2.2. LDL-C targets
While setting aside fixed LDL-C targets, the current guidelines
assume that moderate or high-intensity statin therapy, once
initiated, will result in at least 30e50% or >50% reduction in
LDL-C, respectively. However, it is well known that individual
responses and tolerability to statin therapy vary considerably,
translating into variable magnitude of LDL-C reduction with
variable degree of CV risk reduction. A patient having sub-
optimal response to a particular statin dose is likely to
benefit from further intensification of life-style measures, an
increment in the statin dose and/or change of statin prepa-
ration to achieve adequate LDL-C reduction. However, in
absence of a reference value, it becomes difficult to determine
whether a particular patient has achieved a desired fall in
LDL-C or not, particularly if the baseline lipid values are not
available. These issues are especially relevant for Asian pop-
ulations in whom lower statin doses are used very frequently
and baseline lipid levels are often difficult to trace. Further-
more, successful achievement of LDL-C goal provides the pa-
tient with a sense of accomplishment, boosts his/her morale
andmotivates him/her further to continuewith the treatment
regimen. At the same time, persistently elevated LDL-C above
the goal can help improve patient compliance to the treat-
ment, particularly the adherence to life-style measures.
Considering these issues, the present consensus document
advocates using a hybrid approach. Fixed LDL-C goals are
defined to provide the treating physicians with a perspective
on the anticipated CV risk in a given individual and to deter-
mine the aggressiveness of therapy. At the same time, among
those high-risk patients who already have baseline LDL-C
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that adequate dose statin therapy be prescribed to achieve at
least 40e50% further reduction in LDL-C. This is also consis-
tentwith the recent AmericanDiabetes Association statement
that continues to recommend fixed LDL-C targets for diabetic
individuals.259
5.2.3. Non-statin drugs
Statins have the most profound effect on LDL-C, while also
lowering TG to a lesser extent and raising HDL-C. As dis-
cussed in the previous sections, of all the available lipid-
lowering agents, statins are known to be the most effective
in reducing CV risk. However, it is also being increasingly
recognized now that persistently elevated non-HDL-C in pa-
tients who have achieved adequate LDL-C reduction with
statins is associated with increased CV risk.74,260 Lowering
non-HDL-C in such patients can potentially lead to further CV
risk reduction. As fibrates have potent action on triglycerides
(and therefore non-HDL-C), they have been evaluated for this
purpose. Two large trials-the FIELD and the ACCORD-studied
fenofibrate, the most commonly used fibrate in clinical
practice, in diabetic patients.134,221 While most patients in
the FIELD trial were not on any statin, in the ACCORD study,
fenofibrate was added on top of simvastatin. In both these
trials, fenofibrate did not result in any significant reduction in
the primary end-point in the overall study populations, but
those with atherogenic dyslipidemia (increased TG and low
HDL-C) derived significant benefit.134,222 Furthermore, feno-
fibrate also reduced the risk of microvascular complications
of diabetes.221 Other large fibrate trials have also shown
similar CV risk reduction in patients with atherogenic dysli-
pidemia.135 These observations render fenofibrate a useful
agent for lipid management in Indians in whom atherogenic
dyslipidemia is widely prevalent. Considering this, the pre-
sent consensus committee advocates use of fenofibratein
patients who continue to have elevated non-HDL-C despite
adequate dose of statin therapy and intensive life-style
measures. However, at the same time, it must be re-
emphasized that treatment with any non-statin lipid
lowering agent should not be happen at the cost of adequate
statin therapy.6. Special situations
6.1. Diabetes mellitus
6.1.1. Type 2 diabetes
Type 2 diabetes is a common co-morbid condition encoun-
tered in the lipidology clinic. It is a major risk factor for CVD
and increases the risk of CVD by five times in women, and
three fold in men. It has been demonstrated that people with
diabetes and no history of MI have a CV risk nearly equivalent
to those without diabetes and a history of MI.67 The mecha-
nisms postulated to cause rapid development of vascular
disease in diabetes include hyperglycemia, hypertension, low
HDL-C, high triglyceride levels, elevated small-dense LDL,
increased pro-coagulant activity and a pro-inflammatory
milieu.261 It stands to reason, therefore, that lipid manage-
ment is an essential part of diabetes care.6.1.1.1. Screening and investigations. As mentioned above,
people with diabetes are classified as high risk patients for
vascular events. Hence, irrespective of the presence or
absence of other risk factors on history (age, gender, smoking,
hypertension, family history) or physical examination
(obesity, hypertension, polycystic ovary syndrome inwoman),
they should be screened for dyslipidemia.
A fasting lipid profile should be performed annually. The
minimum investigations should include TC, LDL-C, TG, and
HDL-C. Non-HDL-C should be routinely calculated in these
patients given the higher prevalence of elevated triglycerides
and small-dense LDL among diabetics. In addition, estimation
of Apo-B levels is also desirable in these patients. However,
routine assessment of these markers is not mandatory.
6.1.1.2. Goals of therapy. As all patients with type2 diabetes
with evidence of target organ damage or other CV risk factors
and those with type 1 diabetes with microalbuminuria are
automatically designated to high risk category, they require
management which is similar to that for secondary preven-
tion of CVD.67,68 In other patients, formal risk assessment
may be needed. The treatment approach is broadly same as
that for any high risk individual without diabetes, as
described in the previous sections. The primary target is LDL-
C, while non HDL-C, HDL-C and apoB are secondary targets.68
The present document reiterates the fact that these goals are
global, i.e. for both genders and for all adults. However, in
children and adolescents, the acceptable LDL-C level is
relaxed to 110 mg%.68,261
6.1.1.3. Non-pharmacological therapy. Management of dysli-
pidemia in diabetes is similar to that in people without dia-
betes. Non-pharmacological therapy viz physical activity,
cessation of smoking, and healthy nutrition therapy are
important aspects of therapy and should follow the same
principles as outlined in the previous sections. However, it
should be noted that dietary fructose leads to hyper-
triglyceridemia if consumed in excess of 10% of total energy
intake, in spite of its low glycemic index. Therefore, a careful
dietary review focusing on fructose intake is required for all
persons with hypertriglyceridemia.
6.1.1.4. Pharmacological therapy
6.1.1.4.1. Statins. The choice of drug therapy is similar in
dyslipidemic persons with and without diabetes.261,262 The
present guidelines strongly recommend statin therapy despite
the fact that certain studies document a rise in incidence of
diabetes with these drugs. Meta-analysis has shown that
statin use is linked to a higher (9%) risk of development of new
e onset diabetes, especially in older persons. However, the
risk: benefit ratio of statins is strongly tilted in favor of drug
use.263
Although the choice of statin in diabetes is broadly similar
to that in people without diabetes, there are some important
differences in the impact of different statins on the glycemic
control. Glucose neutral effects have been reported for pra-
vastatin. Simvastatin has been show to inhibit glucose-
induced insulin secretion through blockade of L-type Ca2þ
channels in b cells. Atorvastatin is thought to suppress
glucose transporter GLUT4 expression in 3T3_L1 adipose cells
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cell have also been reported for atorvastatin. Another postu-
lated mechanism is through activation of SREBPs (Sterol
Regulatory Element-Binding Proteins). Pitavastatin use has
been reported to be devoid of the adverse effects on glycemia
that are reported with atorvastatin. Pitavastatin, in fact,
demonstrated a beneficial effect on HbA1c in subjects with
diabetes who were enrolled in the LIVES study.264 Differences
in the metabolic pathways for various statins may explain
these differential effects on glycemic control. Pitavastatin is
minimally metabolized by the CYP3A4 isoenzyme, unlike
other statins, and this may be responsible for its glucose-
neutral character.
The patients with diabetes often have multiple co-
morbidities and are recognized to be in a ‘poly-medicated’
state. Therefore, lipid therapy in diabetics should have low
risk of drugedrug interactions. While most statins are safe,
one should be aware of potential drugedrug interactions.
Antifungal agents such as itraconazole, commonly prescribed
in diabetes, may increase atorvastatin and simvastatin con-
centrations by inhibiting CYP3A4, which metabolizes these
statins.
6.1.1.4.2. Fibrates. Fenofibrate is the most widely used
fibrate compound, and is recommended for use as add-on to
statins. Addition of fenofibrate to statin therapy may benefit
patients with diabetes, hyperglyceridemia and low HDL-
C.134,221Gemfibrozil can also be used in patients with TG
>200 mg% and HDL-C <40 mg%, who do not respond to statin
monotherapy. However, it does not offer any advantages as
compared to fenofibrate. Monotherapy with fibrates is sug-
gested only in patients with isolated hypertriglyceridemia
who do not tolerate statin therapy, even at low doses.
6.1.1.4.3. Other drugs. Colesevelam, is a bile acid seques-
trant, is a lipid-lowering drugwhich has been approved for use
as an oral hypoglycemic agent as well.265 However, this does
not make it a first line drug for use in dyslipidemia compli-
cated by diabetes. Cholesterol absorption inhibitors (e.g. eze-
timibe) have no impact on glycemia, and can be used in
combination with statins. Niacin is not recommended for use
now.
6.1.1.5. Choice of anti-diabetic drugs. Insulin, when used to
manage hyperglycemia, also corrects hypertriglyceridemia.
Similarly, management of insulin resistance helps manage
dyslipidemia as well.261 Diabetic patients with severe hyper-
triglyceridemia (>440 mg%) should be admitted if symptom-
atic, or at risk of developing acute pancreatitis, and started on
insulin therapy to achieve tight glycemic control.
Although pioglitazone has been shown to have beneficial
effects on lipids,266 there have been questionsmarks about its
safety, particularly the risk of bladder cancer. Additionally,
pioglitazone is also not safe in patients with heart failure.
Incretin-based therapy, including the glucagon-like peptide 1
analogs (liraglutide, exenatide) and gliptins (vildagliptin,
alogliptin, sitagliptin) also improve deranged lipid levels in
patients with diabetes. This effect is likely mediated through
reduction in lipolysis and an improvement in the metabolismof postprandial intestinal triglyceride-rich lipoprotein
particles.267
6.1.1.6. Special situations within diabetes. Statins are safe to
use in non-alcoholic steatohepatitis, with mild to moderate
elevation of liver enzymes. Obese individuals with diabetes
and dyslipidemia should be treated in a manner similar to
those without other features of metabolic syndrome. Ator-
vastatin has been shown to have relatively less benefit in
obese persons in the REVERSAL (Reversal of Atherosclerosis
with Aggressive Lipid-Lowering Therapy) study268 and
CHIBA trial.269 The lipophilic nature of the drug may pro-
mote drug redistribution in the adipose tissue, thus reducing
its efficacy. Pitavastatin has been reported to have better
results in obese persons. This effect may be due to an in-
crease in lipoprotein lipase expression in 3T3-L1 pre-
adipocytes, which is otherwise suppressed in insulin
resistance.
6.1.1.7. Monitoring. In persons who experience deterioration
of diabetes control and/or considerable weight gain, frequent
lipid estimations are advisable. Lipid profile can be checked at
6 weekly intervals till goals are achieved. People with sudden
worsening of glycemia after initiation or escalation of statin
therapy may benefit from temporary cessation of the offend-
ing drug, or substitution with another statin molecule with
different metabolism.
Liver enzymes should be assessed along with routine dia-
betes monitoring, especially before and 3 months after initi-
ation of pharmacotherapy. Creatine Kinase should be
measured only in patients with myalgia. Bile acid seques-
trants (cholestyramine, colestipol, colesevelam) may reduce
blood glucose and increase TG, and careful monitoring should
be done in patients with diabetes.
6.1.2. Pre diabetes
As the underlying pathophysiology is similar, the patients
with pre-diabetes (i.e. impaired fasting glucose or impaired
glucose tolerance) are equally prone to develop CVD, as are
thosewith frank diabetes. Hence, the treatment strategies and
goals of management are also the same.261
6.1.3. Type1 diabetes
Patients with type 1 diabetes develop atherosclerosis earlier
than others, with a more rapid progression, and experience
higher premature mortality due to vascular disease. This is in
spite of the fact that they enjoy higher HDL-C levels and rarely
exhibit insulin resistance. This apparently ‘healthy’ profile,
characteristic of type 1 diabetes, is explained by the action of
exogenous insulin therapy. Insulin increases lipoprotein
lipase activity in skeletal muscle and adipose tissue, which
catabolizes VLDL-C, and reduces TG and LDL-C. The para-
doxical increase in CVmortality is due to atherogenic changes
in the composition of HDL and LDL particles.68 The factors
associated with increased risk of CVD in type 1 diabetes
include proteinuria, previous history of MI, high HbA1c
>10.4%, prolonged duration of disease (>16years), presence of
metabolic syndrome, and elevated high-sensitive CRP >3.0mg
% levels.67,68,190
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ried out from the age of 12 onwards, in fasting state, only after
stabilizing diabetes. If there is a family history of hypercho-
lesterolemia, early CVD or if the family history is unknown,
screening should start at the age of 2 years itself. If normal
results are obtained, screening should be repeated every 5
years, till adulthood, and yearly thereafter.270
6.1.3.2. Goals. There is a controversy regarding goals for lipid
levels in children with type 1 diabetes. While the American
Academy of Paediatrics, and American Association of Clinical
Endocrinologists support softer LDL-C targets (normal
<110 mg/dl, high >130 mg/dl, borderline 110e130 mg/dl), the
International Society for Pediatric and Adolescent Diabetes
suggests that the target for LDL-C should be <100 mg/dl. The
presentdocument supports the same target levels for lipids,
irrespective of age, gender or type of diabetes.
6.1.3.3. Management. Management of dyslipidemia in type 1
diabetes is similar to that of type 2 diabetes. If interventions
to improve metabolic control and dietary changes fail to
achieve the targets, statins should be considered, though
long-term safety is not established. Rosuvastatin, atorvasta-
tin and simvastatin are approved for use above 10 years of
age, while colesevalam is approved in children aged 8 years
and more.
6.2. Metabolic syndrome
The metabolic syndrome is a constellation of closely-linked
metabolic and hemodynamic abnormalities, including cen-
tral obesity, dyslipidemia, hyperglycemia and hypertension,
and is associated with increased CV risk. Apart from these
common abnormalities, metabolic syndrome has also been
shown to be associated with hyperuricemia, polycystic
ovarian syndrome and non-alcoholic steatohepatitis, etc.271
Although insulin resistance is a key abnormality in meta-
bolic syndrome, the exact relationship between insulin
resistance and the cause of the metabolic syndrome re-
mains unclear at present. The new data reveals that it
possibly has origins in an adverse lifestyle in the early years
of life.272
Dyslipidemia is an integral component of metabolic syn-
drome and is a risk factor for atherosclerotic vascular disease.
Therefore, appropriate management of dyslipidemia is an
important goal of treatment in these patients.
6.2.1. Diagnosis and general management of the metabolic
syndrome
Worldwide, modified ATP-III criteria are being used for the
diagnosis ofmetabolic syndrome, with different cut-off values
for different ethnic groups.273 These criteria have been
appropriately modified for Indian population also.274
Though the presence of themetabolic syndrome heightens
CV risk, it remains controversial whether itimparts incre-
mental risk over and above its individual components. For this
reason, several investigators have questioned the clinical
utility of the diagnosis “metabolic syndrome” itself. Indeed, in
a recent proposal to the WHO, experts opined that the term
metabolic syndrome be used only for research, and not toguide clinical practice.275 The experts also cautioned against
applying the diagnosis ofmetabolic syndrome to subjectswith
established coronary disease. Nevertheless, the present
consensus document proposes some practical suggestions to
manage dyslipidemia in these subjects.
6.2.2. Screening
Screening for dyslipidemia should be carried out annually in
all persons with one or more features of metabolic syndrome,
viz, diabetes, obesity and hypertension. Presence of any
feature of metabolic syndrome should trigger a careful
assessment of associated features. The minimum screening
evaluation recommended in persons with metabolic syn-
drome is a fasting lipid profile, consisting of TC, TG, HDL-C
and LDL-C. Metabolic syndrome is characterized by eleva-
tion of triglycerides, Apo B, small-dense LDL, as well as a fall in
HDL-C and Apo A1. Therefore, estimation and correction of
non-HDL-C is very important in these patients. In addition, as
in diabetics, measurement of Apo B levels may be desirable
but not routinely recommended.
Assessment and relatively more frequent follow up of lipid
levels is indicated in the following clinical or laboratory situ-
ations in metabolic syndrome-
1. Clinical
 rise in blood pressure
 worsening of glycemia
 gain in weight
2. Drug-related
 addition
 discontinuation
 significant change in dose of anyanti-hypertensive, anti-
diabetic, anti-obesity drug, or other drug expected to
have a(n)-B effect on lipid levels
B drugedrug interaction with lipid-lowering therapy3. Biochemical
 worsening of HbA1c
 rise in liver enzymes
6.2.3. Goals of therapy
The targets for therapy are similar to those in patients without
metabolic syndrome. The primary therapeutic goal is
normalization of LDL-C, while non HDL-C and Apo B are sec-
ondary therapeutic objectives.
6.2.4. Management
Eulipidemic obesity itself is not an indication for pharmaco-
logical lipid lowering therapy and therefore not all patients
with metabolic syndrome need lipid lowering therapy. The
need and the choice of lipid-lowering therapy should be
guided by the severity and the pattern of dyslipidemia.
Lifestyle modification, consisting of physical activity and
nutrition, is extremely important for these patients, particu-
larly when lipid levels are significantly deranged. Drugs
should be initiated in those who have dyslipidemia, and in
normolipidemic persons aged >40 years who have concomi-
tant diabetes (to keep the LDL-C levels below 100 mg/dl).
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pillar of management, both for metabolic syndromeitself and
for dyslipidemia. Weight reduction improves insulin sensi-
tivity, and favorably affects lipid levels. Maximal effect is
observed on TG (20e30%), with HDL-C (0.4 mg% increase per
kg body weight lost) and LDL-C (0.8 mg % fall per kg body
weight loss) showing lesser benefit. Exercise per se has sig-
nificant effects on HDL-C (3.1e6 mg% increase in HDL-C with
1500e2200 kcal/week of aerobic exercise), but not on LDL-C.
6.2.4.2. Pharmacological management of dyslipidemia. The
choice of therapy for dyslipidemia is based upon the type of
lipid abnormality and not the presence or absence of various
components of metabolic syndrome. The dosages of lipid-
lowering therapy also depend upon the extent of lipid-
lowering required, not upon body weight, blood pressure, or
glycemia.
Statins do not affect body weight and can be used irre-
spective of body mass index. Bile acid sequestrants, such as
colesevalam, improve glycemia and are approved for use as
anti-diabetic drugs aswell. However, this alone does notmake
them drug of choice in metabolic syndromewith diabetes and
dyslipidemia, as there is a paucity of event-driven randomized
controlled trial data with these medications. The presence or
otherwise of metabolic syndrome does not impact the choice
of, or dosage of, statins or ezetimibe or fibrates.
Summary. The metabolic syndrome is a cluster of risk
factors that heighten CV risk. There is no large multicenter
randomized controlled study of CV outcomes in persons with
metabolic syndrome. In the absence of such data, the treat-
ment of the metabolic syndrome should continue to be
tailored according to the various individual components of
metabolic syndrome. In subjects with type 2 diabetes, estab-
lished atherosclerotic vascular disease, or severe obesity, the
diagnosis of metabolic syndrome is not really relevant, as
treatment, including lipid management, will be based ac-
cording to these concomitant conditions.
6.3. Acute coronary syndrome
Acute coronary syndrome (ACS) continues to present a major
challenge to clinicians because of its increasing incidence and
because of the subsequent high risk of recurrent ischemic CV
events. As most of the acute coronary events result from
rupture of non-obstructive plaques, preventive strategies,
including lipidmanagement, assume critical importance after
ACS and early and intensive lipid modifying therapy is
considered to be mandatory after an acute coronary event.
6.3.1. Effect of recent acute coronary syndrome on lipid and
lipoprotein measurements
To determine the relationship between plasma lipids and li-
poproteins and prognosis after ACS and to guide a rational
approach to therapy, lipids and lipoproteins need to be ideally
measured under steady-state metabolic conditions. However,
ACS is often accompanied by an acute systemic inflammatory
response, manifest by fever, leukocytosis, elevation of eryth-
rocyte sedimentation rate, and an alteration in the profile of
plasma proteins known as the acute-phase reactants. Someacute-phase reactants, such as CRP, increase in concentra-
tion, while HDL and LDL decrease, resulting in a decrease in
HDL-C and LDL-C levels. The time course of lipoprotein
changes after ACS has been characterized and reviewed by
Rosenson.276 The levels may begin to decrease within 24 h
after an ACS event, particularly among those with more
extensivemyocardial necrosis, reach a nadir at approximately
1 week and then gradually recover.277,278 A metabolic steady-
state is usually re-attained by 1 month following ACS.279,280
The most pronounced lipid changes seen after ACS are-
decreased levels of LDL-C, a similar decrement in HDL-C and
a smaller increase in TG and Lp(a). The magnitude of changes
is variable & is related to the extent of myocardial necrosis,
with the largest changes generally observed after extensive
transmural MI& smaller to insignificant changes after limited
infarction or unstable Angina. After an extensive MI, it is not
uncommon to observe a nadir in LDL-C that is 30% or more
below baseline. Concurrent drug therapy may also influence
lipid measurements after ACS. For example, initiation of beta-
blocker therapy may contribute to a rise in TGs. The practical
implications of all these acute phase effects is that, after an
acute coronary event, accurate measurement of lipid levels is
best made either at the time of presentation or several weeks
later. Nonetheless, it is fair to say that if LDL-C levels are
higher than desirable during acute phase following ACS, they
will almost certainly be undesirably high during metabolic
steady state.
6.3.2. Is there any influence of lipoprotein and lipids on long &
short term prognosis after ACS?
There is strong epidemiological data linking elevated levels of
atherogenic lipoproteins particularly LDL-C& reduced levels of
protective lipoproteins particularly HDL-C to initial develop-
ment of CHD. Similarly, in patients with stable CHD e.g. pa-
tients with stable angina pectoris, remoteMI or prior coronary
revascularization, substantial evidence from observational
studies & placebo controlled trials of statins indicates that
long term prognosis is adversely affected by derangement of
plasma lipoproteins. Relationship between high LDL-C and
low HDL-C with CV events persists among patients treated
with statins in randomized trials.
In ACS, the scenario is different. Each 1 mg/dl increase in
LDL-C measured 1e4 days after ACS (prior to assignment to
statin or placebo), the hazard ratio for an ischemic CV event
has been 1.0 i.e. a null relationship, supporting the lack of
relationship between LDL-C& short term prognosis after ACS.
The absence of a relationship between LDL-C levels & short
term risk is likely to be the result of 2 counterbalancing fac-
tors. On one hand, higher levels of LDL-C may be associated
with increased risk through promotion of atherosclerosis,
while on the other, lower levels of LDL-C may indicate greater
acute phase depression of LDL-C resulting from larger infarcts
and therefore associated with increased risk.
6.3.3. Evidence supporting early and intensive statin
treatment after acute coronary syndrome
Until recently, lipid-lowering drug therapy was viewed as a
long-term strategy to reduce CV risk, rather than an inter-
vention to be employed in the short-term management of
patients after ACS. The conventional viewpoint was based on
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promotes gradual removal of lipid from atherosclerotic pla-
ques, leading to gradual, modest regression of arterial steno-
ses. The conventional view was also based on landmark
clinical trials that established the efficacy of statin treatment
in reducing CVmorbidity andmortality in patients with stable
coronary heart disease. These landmark trials included the
Scandinavian Simvastatin Survival Study (4S),281 Cholesterol
and Recurrent Events (CARE) study,279 Long-Term Interven-
tion with Pravastatin in Ischemic Disease (LIPID) study,280 and
Heart Protection Study.282 In each of these trials, patients with
ACS within preceding 3e6 months were excluded and 1e2
years of statin treatment was required before a reduction in
events could be discerned. Furthermore, all these trials
employed moderate intensity statin treatment such as pra-
vastatin 40 mg daily or simvastatin 20e40 mg daily. However,
in ACS population, potentially modifiable pathophysiological
changes in the vessel wall occur at a much faster pace. Both
experimental and clinical evidence indicate that statins have
the potential to act rapidly to normalize the interface between
blood stream and the vessel wall. Such effects include anti-
inflammatory actions, improvement in endothelial integrity
and function, antithrombotic effects and favorable plaque
remodeling. These effects are independent of the concurrent
reduction of LDL-C and are themost pronounced at high doses
of statins. It is therefore possible that high intensity treatment
(i.e. the highest doses and/or use of the most potent statins),
when initiated early after ACS, can result in potential benefit
in terms of CV risk reduction.
6.3.3.1. Observational data supporting statin treatment after
acute coronary syndrome. The clinical evidence supporting
early statin therapy after ACS consists of observational an-
alyses & randomized controlled trials. The former category
generally supports a benefit of early statin therapy, but in-
dividual analyses vary widely in magnitude of the estimated
effect. A Swedish cohort of 20,000 patients who suffered first
MI was followed prospectively for 1 year. After adjusting for
42 covariates & a propensity score for statin use,prescription
of a statin drug at hospital discharge was associated with a
reduction in 1-year mortality compared with discharge
without statin treatment (relative risk 0.75; p ¼ 0.001).283
Similar findings were obtained in a multivariate analysis of
more than 20,000 patients with ACS enrolled in the GUSTO
(Global Use of Streptokinase or t-PA for Occluded CoronaryTable 14 e Major randomized controlled trial of statins after ac
Trial, year n Statin Compara
MIRACL, 2001285 3086 Atorvastatin 80 mg Placebo
FLORIDA, 2002286 540 Fluvastatin Placebo
PROVE-IT TIMI 22, 2004287 4162 Atorvastatin 80 mg Pravastatin 4
A to Z, 2004288 4497 Simvastatin 40 mg Placebo þ
simvastatin 2
PACT, 2004289 3408 Pravastatin 20e40 mg Placebo
A to Z¼Aggrastat to Zocor, FLORIDA- Fluvastatin on Risk Diminishing after
Aggressive Cholesterol Lowering, NS- not significant, PACT- Pravastati
Atorvastatin Evaluation and Infection TherapyeThrombolysis In MyocarArteries) and PURSUIT (Platelet Glycoprotein IIb/IIIa in Un-
stable Angina: Receptor Suppression Using Integrilin Ther-
apy) studies. Use of lipid lowering therapy at hospital
discharge was associated with odds ratio of 0.67 (P ¼ 0.02) for
death at 6 months compared with no lipid lowering
therapy.284
6.3.3.2. Randomized clinical trials of statins in ACS. There are
six large randomized trials conducted in ACS patients (Table
14). Out of these, 3 large trials- MIRACL (Myocardial Ischemia
Reduction with Aggressive Cholesterol Lowering),285 A-to-Z
(Aggrastat to Zocor)288 and PROVE-IT TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection TherapyeThrombolysis
In Myocardial Infarction 22)287- provide the foundation for our
current understanding of the role of statins after ACS. None of
these trials imposed a lower limit on total or LDL-C at base
line, and each had an upper limit of TC at randomization of
240e270 mg/dl. The MIRACL trial showed that early and
intensive statin therapy after ACS was an efficient and effec-
tive intervention. The 4 months composite endpoint of death,
reinfarction, cardiac arrest, or recurrent unstable angina was
reduced from 17.2% in placebo group to 14.6% in the atorvas-
tatin 80 mg group.285 In the PROVE-IT TIMI 22 study, the
composite endpoint of death, reinfarction, stroke, recurrent
unstable angina or unanticipated coronary revascularization
was reduced from 26.3% in the pravastatin 40 mg group to
22.4% in the atorvastatin 80 mg group at 2 years (p ¼ 0.005).
The difference between the event rates in the two groups
became statistically significant at 6-months.287 Thus, MIRACL
trial demonstrated superiority of high intensity statin over
placebo in a 4 month period following ACS whereas PROVE-IT
TIMI 22 demonstrated superiority of high intensity statin
treatment over moderate intensity treatment over a 2-year
period following ACS. In contrast, the results of A-to-Z trial
did not show any significant benefit of moderate intensity
treatment over placebo early after ACS. During the 4 month
placebo controlled phase of A-to-Z, event rates were 8.2% in
the simvastatin 40 mg group & 8.1% in the placebo group.
However, in the active comparator phase of A-to-Z, high in-
tensity statin treatment provided greater benefit than mod-
erate intensity statin treatment. Treatment with simvastatin
80 mg from 4-months to 2 years resulted in significantly fewer
events compared with treatment with simvastatin 20 mg over
this period of time. Thus, A-to-Z also supports the efficacy of
high intensity statin treatment after ACS.288ute coronary syndrome.
tor Duration Mean LDL-C
(mg/dl; statin v/s
comparator)
% Of primary event
(statin v/s comparator)
4months 72 v/s 135 14.8 v/s 17.4
1 yr 104 v/s 151 33 v/s 36 (NS)
0 mg 2 yrs 62 v/s 95 22.4 v/s 26.3
0 mg
4 months 66 v/s 81 14.4 v/s 16.7
1 month Not measured 11.6 v/s 12.4 (NS)
Myocardial Infarction, MIRACL-Myocardial Ischemia Reduction with
n in Acute Coronary Treatment, PROVE-IT TIMI 22- Pravastatin or
dial Infarction 22.
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treatment reduces early recurrent events after ACS?. Unfortu-
nately, data from 3 key randomized trials do not support such
a simple explanation. In fact, at 4 months of randomized
treatment in the A-to-Z trial, average LDL-C concentration
was 62 mg/dl in the simvastatin 40 mg group & 124 mg/dl in
the placebo group, while at the same time point in theMIRACL
trial, LDL-C averaged 72mg/dl in the atorvastatin 80 mg group
& 135 mg/dl in the placebo group. Thus, the difference in LDL-
C between active treatment & placebo groups was nearly
identical in both trials (62-62 mg/dl) but atorvastatin at 80 mg
reduced clinical events in MIRACL while simvastatin 40 mg
did not in A-to-Z. Moreover, analysis of MIRACL did not
demonstrate a relationship between LDL-C concentration
during randomized treatment & risk of an ischemic
event.285,288 Thus, it appears that factors other than LDL-C
reduction determine whether statin therapy is beneficial in
the early period after ACS.
6.3.4. Should CRP or other inflammatory markers be targets
of therapy after ACS in addition to low density lipoprotein
cholesterol?
The role of inflammation in the pathogenesis of atheroscle-
rosis, the relationship between risk after ACS& elevated levels
of inflammatorymarkers such as CRP& the beneficial effect of
statins on CRP levels lead to the question of whether CRP (or
other inflammatory biomarkers) should be the primary target
of therapy in patients with ACS. Current data do not support
such an approach, at least in regard to CRP. The conventional
paradigm is that inflammation in the arterial wall leads to
release of nanogram per liter quantities of inflammatory cy-
tokines such as interleukins, which act on the liver to stimu-
late synthesis & release of milligram per liter quantities of
CRP. Thus, the liver amplifies inflammatory stimuli from sites
such as the vasculature, which are then reflected by circu-
lating CRP concentrations. While this paradigm may explain
the relation between atherosclerosis & elevated levels of CRP,
the reduction of CRP with statin therapy may not necessarily
reflect suppression of vascular inflammation. This is because
statins exert direct effects on the liver to suppress CRP
expression. Therefore, it is possible that reduction in CRP with
statin therapy primarily reflects suppression of hepatic CRP
production rather than attenuation of vascular inflammation.
In sum, CRP has been validated as a risk marker after ACS, but
not yet as a primary target of therapy.
6.3.5. Safety of intensive statin therapy in ACS
Atorvastatin 80 mg has been proven to be remarkably safe in
large clinical trials. In the combined atorvastatin 80 mg arms
in the MIRACL, PROVE-IT and TNT (Treat eto-New-Target)
trials, there weretotal six cases of rhabdomyolysis in 59000
patient-years of assigned treatment, an incidence no higher
than that with placebo. Thus, vast majority of patients with
ACS can be treated safely with higher doses of statins. How-
ever, it is important to recognize the factors that increase the
risk of rhabdomyolysis, such as advanced age, renal or hepatic
dysfunction, hypothyroidism, etc.
There have been concerns about the safety of high-dose
statin therapy in Asians. Although no causal link could beestablished, an increase in cancer mortality and hemorrhagic
stroke has been reported in some of the studies, particularly
those involving Japanese populations.253,255e257Recently, a
short-term (12 weeks) randomized study comparing two
different doses of atorvastatin (80 mg and 40 mg) was con-
ducted in Indian patients presenting with ACS.258 Both doses
of atorvastatin were well tolerated with no dose-related dif-
ferences in incidence of adverse events between the two
treatment groups. No patient had elevation of (3 times of
upperlimit of normal) liver enzymes or creatinine phospho-
kinase whereas only one patient on atorvastatin 80 mg com-
plained ofmyalgia. However, as mentioned above, this was
only a short-term study and involved only 236 patients.
6.3.5.1. Incident diabetes with intensive statin therapy. In a
pooled analysis of data from 5 statin trials (PROVE IT, A-to-Z,
TNT, IDEAL and SEARCH) intensive-dose statin therapy was
associated with an increased risk of new-onset diabetes
compared with moderate-dose statin therapy.290 The odds
ratios were 1.12 (95% confidence interval 1.04e1.22) for the
development of new-onset diabetes and 0.84 (95% confidence
interval 0.75e0.94) for CV events in participants receiving
intensive therapy compared with moderate-dose therapy. As
compared with moderate-dose statin therapy, 498 patients
needed to be treated per year with intensive-dose statin
therapy to result in one new case of diabetes while the num-
ber needed to treat for preventing one new CV event was 155.
Thus, the benefit clearly outweighed the risk of inducing mild
hyperglycemia with intensive statin therapy.
6.3.6. Translating clinical trials to clinical practice
Based in part on the data fromMIRACL& PROVE IT TIMI 22, the
National Cholesterol Education Program recommended an
optional target for LDL-C of less than 70 mg/dl in patients
considered to be at very high risk of CV events, including those
with recent ACS.251 On the surface, this recommendation ap-
pears to be consistent with the finding of the clinical trials in
which LDL-C averaged 62e70 mg/dl in the Atorvastatin 80 mg
arm. However, the PROVE-IT TIMI 22 trial found progressively
lower riskwith progressively lower achieved LDL-C level in the
atorvastatin 80mg arm, extending even to those patients with
LDL-C level less than 40 mg/dl. Therefore, it would appear to
be illogical to attenuate the intensity of therapy to achieve an
LDL-C level of 70 mg/dl when a higher statin dosage might
drive LDL-C even lower. Thus, given the data supporting effi-
cacy & safety of high intensity statin treatment after ACS, it
would be reasonable to apply this strategy of initiation of high
dose statin therapy to themajority of patients presenting with
ACS, rather than titrating the intensity of statin treatment to
achieve an LDL-C level of 70 mg/dl. In all patients, the goal of
the treatment should be to achieve at least 40e50% reduction
in LDL-C, irrespective of the baseline levels.
In Indians also, it is recommended that high-dose statin
therapytobeprescribed toallpatientspresentingwithanacute
coronary event.However, as the data about safety of high-dose
statin therapy in Indians is limited toonly3months'period, it is
reasonable to reduce statin dose,3 months after initial pre-
sentation with ACS, to levels sufficient enough to sustain
desired LDL-C reduction (at least 40e50% from baseline).
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The number of patients with chronic kidney disease (CKD) is
increasing but the survival of these patients remains dismal,
largely due to premature CVD. As a matter of fact the risk
attributable to CKD is so high that it deserves to be considered
tobe a ‘CAD risk equivalent’ and the risk factors should be
managed accordingly.291
6.4.1. Target population
CKD is defined according to the presence, for at least 3
months, of either of the following:
1. Structural or functional abnormalities of the kidneys, with
or without decreased GFR. These abnormalities are man-
ifested either as pathological abnormalities or markers of
kidney damage, including abnormalities in the composi-
tion of blood or urine, or abnormalities in radiographic
imaging tests.
2. GFR <60 ml/min/1.73 m2.
The definitions of stages 1e5 CKD are based on measured
or estimated GFR, where the GFR is estimated from the serum
creatinine using an established formula, as described in the
NKF K/DOQI (National Kidney Foundation Kidney Disease
Outcomes Quality Initiative) CKD Guidelines.292
 Stage 1 CKD is defined as estimated GFR  90 ml/min/
1.73m2, with evidence of kidney damage (as defined above).
 Stage 2 CKD is defined as evidence of kidney damage with
mildly decreased GFR of 60e89 ml/min/1.73 m2.
 The level of estimated GFR, with or without kidney dam-
age, defines stages 3e4 (30e59 and 15e29 ml/min/1.73 m2,
respectively).
 Stage 5 (kidney failure) is defined as GFR <15 mL/min/
1.73 m2, or the clinical indication for renal replacement
therapy in the form of maintenance hemodialysis, perito-
neal dialysis, or transplantation.
Thus, some Stage 5 patients may need renal replacement
therapy because of uremic symptoms, even when, based
solely on GFR they would be classified in stage 4 (GFR
15e29 mL/min/1.73 m2). An interesting sub-set is kidney
transplant patients who have normal kidney function
(GFR  90 mL/min/1.73 m2) and therefore may not have CKD
according to the conventional CKD criteria. In addition, they
may also not have evidence of kidney damage, i.e. they have
normal urine protein excretion, urine sediment, histology,
and radiographic imaging. However, these patients are still at
increased risk for CKD related complications and thus
considered within the scope of this guideline.
6.4.2. CKD and dyslipidemia
Patients with CKD have high prevalence of dyslipidemias and
CAD293e296 and the general guidelines for management of
CVD, such as the updated guidelines of the ATP III,67 are
applicable to patients with stages 1e4 CKD as well (Table 15).
However, as mentioned above, CKD needs to be classified as a
CAD risk equivalent and the management approach needs be
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S36modified accordingly. Apart from this, there are some addi-
tional issues that need to be considered-
 Relation between dyslipidemia and mortality in CKD
 Therapy for dyslipidemia in CKD
 Complications of lipid-lowering therapies that may result
from reduced kidney function
6.4.3. Relationship between serum cholesterol levels and
mortality in CKD
Unlike the patients without CKD, the relationship between
cholesterol levels and CVD mortality in those with CKD is
more complex. A review of observational studies of dialysis
patients demonstrated a reverse relation between TC levels
and risk of all-cause mortality such that lower cholesterol
levels were associated with a higher mortality rate.297 In
another analysis of data from more than 12,000 hemodialysis
patients, patients with low TC levels (less than 100 mg/dl) had
over 4 times the mortality risk of patients with TC levels be-
tween 200 and 250 mg/dl.298 A more recent 10-year prospec-
tive study evaluated the importance of TC levels in 1167
chronic hemodialysis patients in Japan.299 When compared to
a reference group with TC between 200 and 220 mg/dl, hypo-
cholesterolemia was associated with a significantly higher all-
cause mortality rate. Hypocholesterolemia also correlated
closely with low serum albumin and high CRP levels, sug-
gesting that it perhaps served as a surrogate for malnutrition
or inflammation. On the other hand, in patients with high
serum albumin levels, elevated TC was a strong predictor of
CV death. Similarly, in another study of dialysis patients, in
the absence of inflammation and malnutrition, elevated TC
was associated with increased risk of CVD events, while the
presence of inflammation attenuated the relationship be-
tween hypocholesterolemia and CVD.300
6.4.4. Treatment of dyslipidemia in CKD
There are no randomized controlled intervention trials in CKD
patients showing that the treatment of dyslipidemias reduces
the incidence of CVD. Moreover, it is possible that trial results
from the general population may not be applicable to all pa-
tients with CKD. It is also possible that in someTable 16 e Key features of the K/DOQI guidelines that differ fro
NKF K/DOQI guidelines
CKD patients are considered to be in the highest risk category
Evaluation of dyslipidemias should occur at presentation, after a
change in status, and annually
Drug therapy should be used for LDL-C 100e129 mg/dl after only 3
months of TLC
Initial drug therapy for elevated LDL-C should be with a statin
Fibrates may be used in Stage 5 CKD 1) for patients with TG  500; and
2) for patients with TG  200 mg/dl with non-HDL-C 130 mg/dl who
do not tolerate statins
Gemfibrozil may be the fibrate of choice for treatment of high TG in
patients with CKD
CKD, chronic kidney disease; NKF K/DOQI, National Kidney Foundation
Cholesterol Education Program Adult Treatment Panel III; LDL, low-den
lifestyle changes.subpopulations of CKD patients, treatment of dyslipidemias
may not be as safedor as effectivedin reducing the incidence
of CVD, as it is in the general population. This may be due to
the unique complications of CKD (eg, anemia, calcium and
phosphorus metabolic abnormalities) that may contribute to
the risk of CVD in CKD.
Based on the risk reductions achieved in the general pop-
ulation in patients with or at high risk for CVD, the small
amount of existing data in the CKD population, and the
marked risk of CVD in patientswith kidney disease, theNKFK/
DOQI has established guidelines for management of dyslipi-
demia in CKD.292 The important differences between these
guidelines and the ones published by the ATP III are listed in
Table 16. The more recent ACC/AHA guidelines on manage-
ment of dyslipidemia observed that routine administration of
statin therapy did not provide any significant CV benefit in
patients undergoingmaintenance hemodialysis and therefore
did not make any recommendation for statin therapy in these
patients.133 Apart from this, no discussion was provided on
management of dyslipidemia in other CKD patients.
6.4.4.1. Statins in patients with CKD
6.4.4.1.1. Efficacy of statin therapy in reducing lipid levels
in patients with CKD.
6.4.4.1.1.1. Peritoneal dialysis patients. Only3 small trials have
evaluated statin therapy in patients undergoing peritoneal
dialysis. A randomized, placebo-controlled study assessed the
effect of atorvastatin in 177 patients undergoing continuous
ambulatory peritoneal dialysis (CAPD).301 After 16 weeks, pa-
tients receiving atorvastatin experienced greater reductions in
LDL-C and triglyceride levels and significant increases in HDL-C
levels compared with subjects receiving placebo. Another 4-
month, non-randomized study evaluating the effect of ator-
vastatin in 29 hypercholesterolemic patients undergoing peri-
toneal dialysis showed similar results.302 Finally, significant
reductions inLDL-C levels comparedwithplacebowerenoted in
a 24-week randomized study of simvastatin 10 mg/day in 23
patients undergoing CAPD.303
6.4.4.1.1.2. Hemodialysis patients. Four studies to date have
assessed the effect of statin therapy on LDL-C levels in pa-
tients undergoing hemodialysis and all 4 studiesm NCEP ATP III.
ATP III guidelines
CKD patients are not managed differently from other patients
Evaluation of dyslipidemias should occur every 5 years
Drug therapy considered optional for LDL-C 100e129 mg/dl
Initial drug therapy for elevated LDL-C should be with a statin, bile
acid sequestrant, or nicotinic acid
Fibrates are contraindicated in CKD
No preferences for which fibrate should be used for
hypertriglyceridemia
Kidney Disease Outcomes Quality Initiative; NCEP ATP III, National
sity lipoprotein; HDL-C, high-density lipoprotein; TLC, therapeutic
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S37demonstrated that statin therapy reduced LDL-C levels. In one
study, 34 hemodialysis patients randomized to therapy with
simvastatin experienced a large, statistically significant
reduction in LDL-C levels and a smaller but significant
reduction in triglyceride levels compared with placebo.303 An
8-week randomized trial in 58 hemodialysis patients also
noted that simvastatin significantly reduced LDL-C levels,304
while a 24-week, non-randomized study of simvastatin
5 mg/day demonstrated significant reductions in LDL-C levels
in 38 hypercholesterolemic patients.305 Finally, a randomized
study of atorvastatin and simvastatin found that both statins
significantly reduced LDL-C levels.306
6.4.4.1.1.3. Kidney transplant recipients. The use of statins in
kidney transplant patients has been well investigated. In
addition to several small studies that have demonstrated a
significant reduction in LDL-C levels with statins,307e309 the
results of a large, randomized, placebo-controlled trial-the
Assessment of LEscol in Renal Transplantation (ALERT) are
also available.310 After a mean follow-up of 5.1 years, kidney
transplant patients receiving fluvastatin 40e80 mg/day
(N ¼ 1050) experienced a 32% reduction in LDL-C compared
with patients receiving placebo (N ¼ 1052).
6.4.4.1.2. Statins and CVD events.
6.4.4.1.2.1. Stages 2e4 CKD. Few studies have examined this
question in CKD. The best evidence to date comes from a post-
hoc subgroup analysis of the Cholesterol and Recurrent Events
(CARE) study, focusing onpatientswith stages 2e4CKD.311 The
CARE study was a randomized, double-blinded, placebo-
controlled trial of pravastatin in patients with a history of MI
and total plasma cholesterol levels below 240 mg/dl. Among
1711 subjects with estimated creatinine clearance less than
75 ml/min (mean creatinine clearance, 64 ml/min), a 28%
reduction in the composite study outcome ofMI and fatal CHD
was noted in the pravastatin group, but there was no signifi-
cant difference in all-cause mortality. Pravastatin therapy
resulted in similar risk reductions in all subjects regardless of
kidney function as well as in subjects with creatinine clear-
ance less than 60 ml/min.
6.4.4.1.2.2. Stage 5 CKD. No randomized controlled trial to
date has assessed whether statin therapy reduces the rate of
CVD events in dialysis patients. Limited data include a recent
observational study that compared 362 hemodialysis patients
receiving statin therapywith 3354patientsnot receiving statins
andnotedan independent associationbetween statinuseanda
reduced risk of totalmortality andCV-specificmortality.312 The
association between statin use and reducedCVDmortality held
only for patients with known preexisting CVD, and the con-
clusions are limited by the observational nature of the study.
6.4.4.1.2.3. Kidney transplant recipients. To date, only a single
trial (ALERT) has assessed whether there was a reduction in
the rate of CVD events in kidney transplant patients with
statin therapy.307 In this trial, there was a trend towards
reduction in the composite endpoint (cardiac death, nonfatal
MI, or coronary intervention procedure) with fluvastatin as
compared to placebo (relative risk [RR], 0.83; 95% confidence
interval [CI], 0.64e1.06). Therewere significantly fewer cardiac
deaths and nonfatal MIs in the treatment group but no
reduction was seen for coronary intervention procedures,cerebrovascular events, non-CV death, all-cause mortality,
graft loss, or doubling of serum creatinine levels.
6.4.4.1.3. Reducing progression of CKD. Results fromsmall,
randomized trials have demonstrated a potential benefit of
statins with regard to slowing decline in GFR. Ameta-analysis
of 12 trials in subjects with CKD demonstrated that patients
receiving lipid-lowering therapy, primarily statins, experi-
enced significantly lower monthly decline in GFR compared
with controls (0.16 ml/min/month; 95% CI, 0.03e0.29).313 This
study also showed a trend toward a reduction of proteinuria
with lipid-lowering therapy, although there was considerable
heterogeneity among the includedstudies. Ina recentpost-hoc
analysis of a subgroup of 690 patients withmoderate to severe
CKD(estimatedGFR<60ml/minper1.73m2)whowerepartofa
randomized controlled trial, statin therapy slowed the decline
in kidney function, especially in those with proteinuria.314 In
another randomized controlled study, Bianchi et al evaluated
atorvastatin 10e40 mg/day versus no treatment in 56 patients
with CKD receiving antihypertensive medications.315 After 1
year, the rateofproteinuria in theatorvastatin-treatedpatients
decreased significantly compared with baseline (P < 0.01),
while there was no change in proteinuria in the control group.
Notably, there was wide inter-patient variability in efficacy.
In summary, data from several small, randomized
controlled trials indicate that statins effectively reduce LDL-C
levels in patients with CKD. Because of the paucity of clinical
data, it is currently unclear whether statin therapy is associ-
atedwith a reduced rate of CVD events andwhether this effect
is only seen in patients at greatest risk. Although large,
controlled, randomized trials are lacking, statins may confer
other protective effects, such as slowing the decline in GFR or
reducing levels of inflammation.
6.4.4.2. Other pharmacologic therapy in CKD. Fibrates are
indicated when hypertriglyceridemia (serum TG  500 mg/dl)
is the primary lipid abnormality (Table 15), and may reduce
triglyceride levels by up to 30%e50%.67 However, fibrates are
excreted by kidneys and may cause myositis, particularly
when used in conjunction with statins. Therapy with fibrates
may also cause an increase in serum creatinine levels that is
not related to overt muscle injury, although this has not been
observed with gemfibrozil.316 It is uncertain whether this
represents an actual decrease in GFR versus an assay effect, an
alteration in creatinine secretion, or an increase in creatinine
production.317e319http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1492581/-b44.
Nicotinic acid (niacin) is the most efficacious agent for
increasing HDL-C levels in the general population and also has
beneficial effects on triglyceride levels and less significant but
favorable LDL-C-lowering effects. However, the recent expe-
rience with HDL-C raising therapies, including niacin, has
been disappointing and at present, no pharmacological ther-
apy can be considered safe for raising HDL-C.237,320
Bile acid sequestrants work by binding bile acids in the
intestine, blocking distal reabsorption and thereby decreasing
LDL-C levels. Bile acid sequestrants are not well studied in
patients with CKD, but are probably well tolerated given their
lack of systemic absorption. Bile acid sequestrants currently
Fredrickson Classification
Type I Hyperchylomicronemia
Type IIa Familial hypercholesterolemia (FH)
Type IIb Familial Combined
Hypercholesterolemia (FCH)
Type III Dysbetalipoproteinemia
Type IV Fimilial Hypertriglyceridemia
Type V Familial Lipoprotein Lipase
deficiency
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S38are recommended as second-line agents for reducing elevated
LDL-C levels.
6.4.4.3. Safety of pharmacologic therapy in CKD. The treat-
ment of patients with CKD can be quite complex because of
the many co-morbid conditions in this population. Given the
use of multiple medications as well as the changes in meta-
bolism ofmedications, it is important to remain aware of dose
adjustments and potential medication interactions.
Table 17 presents dosing recommendations and several
contraindications for lipid-lowering medications. For statins,
theacceptabledosagevariesaccording to thestatinusedandthe
level of kidney function. In general, statins that are not metab-
olized by the kidneys are well tolerated at all doses. Indeed,
atorvastatin dose of up to 80 mg/day have been shown to pro-
duce no serious adverse events in hemodialysis patients.321
Before initiating statin therapy in CKD patients, it may be
helpful to establish the patient's baseline CPK levels, so that if
adverse effects such as myositis occur, the patient can be
evaluated more readily. If a patient reports muscle pain, sta-
tins should be withdrawn and CPK levels assessed. Patients
with onlymild adverse reactions to their initial statin regimen
could be prescribed the same statin at a lower dosage or
started on a different statin before proceeding to alternative
lipid-lowering therapies.292
Statins are contraindicated for patients with acute or
chronic liver disease and close attention should be paid to
interactions that affect statin metabolism. Agents known to
increase statin blood levels include calcineurin inhibitors,
such as cyclosporine and tacrolimus, which are commonly
used in kidney transplant recipients. Other agents thatTable 17 e Lipid-lowering medication dose adjustments for re
Agents Dose adjustment according to GFR (ml/min/1
60 to 90 15 to 59 <
Statinsa
Atorvastatin None None No
Fluvastatin None Y to 50% Y t
Lovastatin None Y to 50% Y t
Pravastatin None None No
Rosuvastatin None Y Y
Simvastatin ? ? ?
Nicotinic acid None None Y t
Bile acid sequestrant
Cholestyramine None None No
Cholestipol None None No
Colesevelam None None No
Fibratesa
Clofibrate Y to 50% Y to 25% Avo
Fenofibrate Y to 50% Y to 25% Avo
Gemfibrozil None None Avo
GFR, glomerular filtration rate in ml/min/1.73 m2.
a Because of increased risk of myositis and rhabdomyolysis, statin ther
chronic kidney disease.
b The increase in levels of serum creatinine seen with most fibrates hasinteract with statins include macrolide antibiotics, azole
antifungal agents, calcium channel blockers (particularly
nondihydropyridines), fibrates, nicotinic acid, serotonin re-
uptake inhibitors, warfarin, and grapefruit juice. Statin ther-
apy in conjunction with a fibrate can increase the risk of
myositis or rhabdomyolysis; K/DOQI guidelines recommend
avoiding this combination in patients with CKD.2926.5. Familial dyslipidemia
There is a lack of unifying classification of inherited lipid
disorders and therefore, we still continue to use an old clas-
sification laid down by Donald Fredrickson in 1967, despite its
limitations.The above classification system has twomain deficiencies.
Firstly, it is incomplete since it does not includemore recently
discovered genetic disorders which are discussed later under
the group captioned “Non-Fredrickson inherited lipid dis-
eases”. Secondly, many patients with hypertrigly-ceridemia
can be either Type I, IIb, IV or V. Thirdly, it does not includeduced kidney function.
.73 m2) Notes
15
ne
o 50% Decrease dosage by half at GFR < 30
o 50% Decrease dosage by half at GFR < 30
ne Starting dose of 10 mg/day recommended for GFR < 60
Decrease to a maximum of 10 mg/day at GFR < 30;
recommended starting dose is 5 mg/day
Start at 5 mg/day in patients with GFR < 10
o 50% May worsen glycemic control and cause orthostasis,
hyperuricemia, and flushing
ne Not systemically absorbed
ne Not systemically absorbed
ne Not systemically absorbed
id May increase serum creatinineb
[ risk of myopathy
id May increase serum creatinineb
[ risk of myopathy
id Likely no effect on serum creatinine
[ risk of myopathy
apy in conjunction with a fibrate should be avoided in patients with
not been appreciated with gemfibrozil.
Table 18 e Diagnostic criteria for familial
hypercholesterolemia [according to MedPed (Make Early
Diagnosis to Prevent Early Deaths) and WHO].
Category Criterion Score
Family history First-degree relative known with
premature CAD and/or first-degree
relative with LDL-C >95th centile
1
First edegree relative with tendon
xanthomata and/or children <18
with LDL-C >95th centile
2
Clinical history Patient has premature CAD 2
Patient has premature cerebral/
peripheral vascular disease
1
Physical
examination
Tendon xanthomata 6
Arcuscornealis below age of 45
years
4
LDL-C >330 mg/dL 8
250-329 mg/dL 5
190-249 mg/dL 3
155-189 mg/dL 1
Interpretation: Definite FH e score >8; Probable FH e score 6e8;
Possible FH e score 3e5; No diagnosis e score <3.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S39HDL-C and it does not differentiate severe monogenic disor-
ders from more common polygenic disorders.
The Fredrickson classification strictly applies to type I
(Hyperchylomicronemia) and type IIa (Familial hypercholes-
terolemia) disorders. For other Fredrickson subtypes, serum
profile of a single patient can move from one category to
another depending on environmental factors or treatment, as
the extent of enzymatic activity can increase or decrease
depending on the clinical milieu.
6.5.1. Fredrickson type I (Hyperchylomicronemia)322e324
 Frequency:
B Rare inherited disorders with a frequency of 1 in
1,000,000
 Underlying metabolic defect:
B Deficiency of lipoprotein lipase (LPL) or Apo CII deficiency
 Clinical presentation:
B TG usually > 1000 mg/dl, often in children; TC usually 1/
10 of TG
B Blood sample appears lipemic (creamy top layer) and
contains chylomicrons
B Eruptive xanthomas and recurrent pancreatitis
B Low atherogenicity
 Treatment:
B Low fat diet (<20 g/day) with supplementation of diet
with medium chain TG and also provide 1% of total cal-
orie intake as linoleic acid
B Fibrates or omega-3 fatty acids if there is a VLDL-C
component to reduce the degree of hypertriglyceridemia
B Glycemic control in diabetics; insulin activates LPL
B Plasmapheresis in extreme cases
6.5.2. Fredrickson type IIa (familial hypercholesterolemia)68
 Inheritance and Frequency:
B Autosomal dominant (especially French Christians, Leb-
anese Christians and Finns)
B Homozygous 1/1,000,000
B Heterozygous 1/500
B [FH is under-diagnosed; high index of suspicion and
aggressive family testing is a proven way to identify and
treat this potentially fatal disease.
 Underlying Metabolic defect:
B Defective LDL-C-receptor or defective Apo B; the latter is
likely to carry a better prognosis than LDL-C receptor
mutations. While a few mutations in preprotein con-
vertase subtilismkexin 9 (PCSK-9) have been described to
be prognostically poorer, it remains to be seen whether
this is the case for all PCSK-9 activating mutations.
 Clinical presentation and diagnosis:
B There are well defined diagnostic criteria laid down for
familial hypercholesterolemia (Table 18) Treatment:
B Aggressive low saturated fat diet.
B High dose statins (Atorvastatin 40e80 mg, Rosuvasvatin
20e40 mg) or moderate dose statin þ Ezetimibe 10 mg or
moderate dose statinþ colesevelam (625mg tablet 3 tabs
bid)
B Target LDL-C: <100 mg/dL for high risk subjects or
<70 mg/dL in presence of very high risk or established
CVD. If targets cannot be reached, maximal reduction of
LDL-C should be considered using appropriate drug
combinations in tolerated doses.
B In children diagnosed with FH, if family history of
CAD<40 years, start statins (Atorvastatin 10e20 mg or
Rosuvastatin 5e10 mg) at age of 6 years. If family history
of CAD<50 years not present, start statins in samedosage
at age 10e16 years.
B Add ezetimibe or colesevelam as needed to reach at least
50% reduction in LDL-C.
B Monitor atheroma progression e.g. Carotid intima-
medial thickness (cIMT), check for cardiac atheroma;
monitor aortic valve by echocardiography.
B Whendrugs fail, then apheresis or plasmapheresis is used
to physically remove LDL-C and lipoprotein particles
(usually indicated at LDL-C 250 mg/dl despite drug ther-
apy). Apheresis is preferred to plasmapheresis as there is
no need for infusions of albumin or fresh frozen plasma.
B When homozygous FH is diagnosed in young children,
then the usual plan is to restore hepatic LDL-C-receptor
function by liver transplantation as soon child is tech-
nically fit to undergo surgery; if not feasible, some suc-
cess has been reported with portocaval shunts.
B Heterozygous familial hypercholesterolemia (HeFH) is a
treatable cause of early vascular disease and
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1S40pharmacological treatment of HeFH is cost-effective
strategy. Most cost-effective strategy is clinical and
biochemical screening of close relatives of the proband
patient.
6.5.3. Fredrickson type IIb (familial combined
Hypercholesterolemia)325
 Inheritance and Frequency:
B Autosomal dominant
B Frequency: 1/200; commonest frequency in lipid clinics
 Underlying metabolic Defect:
B Hepatic over-production of apo-B leading to increased
plasma VLDL-C
 Clinical presentation:
B TC: 200e400 mg/dl
B TG: 150e500
B HDL-C usually low
B Premature CAD out of proportion to modest degree of
overallhyperlipidemia but high proportion of small-
dense LDL particles
B Apo B > LDL-Cholesterol
B Commonly seen with insulin resistance and metabolic
syndrome
B Xanthomas not seen
 Treatment:
B Lifestyle modification: Check fasting blood sugar and HbA1C
 Limit refined carbohydrates and alcohol
 Monosaturated and Omega-3 fats >> saturated fats
B Drugs:
 Start at mid-level dose of high-potency statin
 Atorvastatin 20 mg, Simvastatin 20 mg, Rosuvastatin
10e20 mg/day
 Check LDL-C, TG, non-HDL-C,and apoB or LDL parti-
cles e if not at goal/ add either fenofibrate or niacin
(check liver function and blood sugar)/ if still not at
goal / combine statin þ fibrate þ niacin (aim for
maximal dose tolerated)
B In families with a severe history of very early coronary
heart disease (<40 years old), screening at age 6 may be
appropriate. Most children can be tested at age 16e18
years.
6.5.4. Fredrickson type III (familial dysbetalipoproteinaemia)
or remnant hyperlipipaemia326
 Frequency:
B Rare
 Underlying metabolic defect:
B Apo E2/E2 does not bind with hepatic B/E receptor
 Clinical presentation:B IDL (VLDL-C remnants) are increased
B Tubero-eruptive xanthomas on elbows and knees
B Orange palmar xanthomas
B TC ~300 mg/dL
B TG ~300 mg/dL
 Treatment:
B Life-style measures, mainly weight loss
B Statins are mainstay of therapy as statins reduce TG in
proportion to their efficacy in reducing LDL-C and baseline
triglyceride levels; however, often triglyceride-lowering
therapy for residual hypertriglyceridemia is required.
B Given the role of insulin resistance in this disorder, there
is also evidence for combining statins with metformin or
thiazolidinediones.
6.5.5. Fredrickson type-IV (Familial
Hypertriglyceridemia)323
 Inheritance and frequency:
B Autosomal dominant
B Common disorder, frequency > 40% in lipid clinics
 Underlying metabolic Defect:
B Impaired lipolysis of TG (? role of apo CIII) or increased
production of VLDL-C
 Clinical presentation:
B Family history of hypertriglyceridaemia
B Exacerbated by high carbohydrate diets and/or alcohol
B Low atherogenicity
B Serum TG > 500 mg/dL
 Treatment:
B Check liver enzymes, uric acid, fasting blood sugar or
HbA1C
B Lifestyle measures: Low fat diet
 Limit refined carbohydrates
 Avoid alcohol
 Daily 30 min of brisk walking
B Drugs
 Start with fenofibrate, niacin or omega 3e4 g; if statins
are likely to be added later, avoid gemfibrozil, unless
renal failure is present.
 Target triglyceride is < 150 mg/dL
 If TG > 1500, start fenobibric acid 145 mg and Omega
3 at a dose of 4 g simultaneously
6.5.6. Fredrickson type V (Familial lipoprotein lipase
deficiency)327
 Frequency and inheritance:
B Rare in general population
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) S 1eS 5 1 S41B Autosomal recessive condition; LPL is the only gene in
which mutation (p.Gly 188 Glu) is known to cause this
condition.
 Underlying metabolic defect:
B Lipoprotein Lipase deficiency
B Both chylomicrons and TG present
 Clinical presentation:
B TC ~250 mg/dL
B TG 2000 mg/dL, childhood onset with episodic abdom-
inal pain
B Recurrent acute pancreatitis, eruptive cutaneous xan-
thomata, hepato-splenomegaly
 Treatment:
B Along the lines of chylomicronemia.6.5.7. Non-Fredrickson inherited lipid disorders
6.5.7.1. Lipoprotein(a) [Lp(a)]. Lp(a) is an Apo-B lipoprotein
with an Apoa attached. It is inherited in an autosomal
dominant fashion. An elevated level of Lp(a) is doubly bad
because (i) it is atherogenic like LDL-C-and (ii) it is pro-
thrombotic because of its similarity to plasminogen.
Although LP(a) levels > 30 mg/dl are generally considered
threshold at which premature CHD increases rapidly, levels
below 20 mg/dl are considered optimum, particularly in
Asian Indians.131
Lp(a) is an independent risk factor for CVD, but is clini-
cally relevant only when the LDL-C is also abnormally
high.328 In the Familial Atherosclerosis Trial Study (FATS)
follow-up, reduction of LDL-C levels to <2.6 mmol/L was
associated with amelioration of the residual risk posed by
Lp(a).329 Best known therapy that reduces Lp(a) by > 20% is
niacin. Estrogen therapy and raloxifane also reduces Lp(a)
levels. Since Lp(a) is fully expressed in the first year of life,
tracking Lp(a) from childhood may be better optionthan
focusing on other dyslipidemias that are not expressed until
later life.
6.5.7.2. Inherited low HDL-C330. Most low HDL-C is not
inherited. Most common causes of low HDL-C include the
pandemic of obesity, inactivity, a high-carbohydrate diet or a
very low-fat diet. Inherited low HDL-C has four causes- (i)
familial hypo-alpha-lipoproteinemia; (ii) Tangier disease-
inherited deficiency of ABCA-1 (ATP-binding cassette
transporter-1); (iii) a deficiency of LCAT (Lecithindcholesterol
acyltransferase); (iv) HDL-Milano. First three may be or
are associated with premature CAD and the last
one, i.e. HDL-Milano is cardio-protective but unfortunately
rare.
6.5.7.3. Inherited elevated HDL-C331. There are three inherited
causes of elevated HDL-C-
 First is almost exclusively seen in people of Japanese
ancestry, is an inherited loss-of-function mutation in theallele for the gene that encodesCETP. CEPTdeficiency occurs
primarily in Japan, where its relationship to CV risk is still
under debate i.e. whether it reduces or increases CV risk.
 Second is inherited hepatic lipase deficiency
 Third is primary hyperalphaliproproteinemia6.5.7.4. Inherited low LDL-C (Hypobetalipoproteinemia)332.
These patients are heterozygotes for hypo-beta-
lipoproteinemia. Homozygotes cannot carry cholesterol to
cells for membrane formation and do not survive. Heterozy-
gotes have an LDL-C that ranges from 25 to 40, and neither do
they develop atherosclerosis nor have any biologic or devel-
opmental problems.
6.5.7.5. Sitosterolemia or Phytosterolemia333. This is a rare
(although probably under-diagnosed) autosomal recessive
lipid disorder characterized by increased absorption of the
plant sterols compesterol and sitosterol and various plant
stanols. This occurs due to mutation in ABCG5 and ABCG8
transporter enzymes which pumps the sterols and stanols
from the enterocytes back into the intestine.
Excessive systemic levels of phytosterols are highly toxic to
cells and there patient have high LDL-C levels since LDL re-
ceptors are down-regulated. Patients with sitosterolemia
present like classic homozygotic FH with tendon xanthomas,
arcussenilis and premature CAD.
6.5.7.5.1. Studies on familial dyslipidemia amongst Indians.
Prevalence of familial hypercholesterolemia (FH) in India is not
known. Till date, 10 different LDL receptor gene mutations
have been reported in the literature.334Most of thesemutations
have been reported in exons 3, 4, 9 and 14 among Indians
settled in South Africa, which suggests an increased frequency
of FH in India.334 The Indians, who migrated to South Africa,
originated from diverse areas in India and they remained iso-
lated in that country primarily as a result of religious and cul-
tural practices. Hence the group in South Africa probably
represents the incidence in the Indian subcontinent.
Ashavaid et al studied DNA samples from 25 hypercho-
lesterolemia patients and using heteroduplex (HDX) analysis,
two patients were found to show an abnormal HDX pattern,
one each in exon 3 and exon 4.335 Genetic investigations of
hyperlipidemia in Asian Indians clearly need more research
attention.Conflicts of interest
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